• Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    • Smith M, Pothuri B.
    • Curr Treat Options Oncol. 2022 Jun;23(6):887-903. doi: 10.1007/s11864-022-00938-4. Epub 2022 Apr 12.
    • Review
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.
    • Review
    • Olaparib for ovarian cancer: a single-institution, multi-site qualitative study.
    • Martin NA, Hanna M, Ehret C, Asiedu G, Jatoi A.
    • Support Care Cancer. 2022 Jun;30(6):4807-4812. doi: 10.1007/s00520-022-06879-w. Epub 2022 Feb 11.
    • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    • Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y.
    • Br J Cancer. 2022 May 26. doi: 10.1038/s41416-022-01836-0. Epub ahead of print.
    • AZD5305 More Tolerable than 1st-Generation PARP Inhibitors.
    • [No author given]
    • Cancer Discov. 2022 May 26:OF1. doi: 10.1158/2159-8290.CD-NB2022-0039. Epub ahead of print.
    • News
    • Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A Case Report.
    • Valls ML, Kase AM, Patel R, Wang B, Aggarwal R, Colon-Otero G.
    • Gynecol Oncol Rep. 2022 May 25;101010. doi: 10.1016/j.gore.2022.101010.
    • Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance.
    • Kyo S, Kanno K, Takakura M, Yamashita H, Ishikawa M, Ishibashi T, Sato S, Nakayama K.
    • Cancers (Basel). 2022 May 19;14(10):2504. doi: 10.3390/cancers14102504.
    • Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    • Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD.
    • Gynecol Oncol. 2022 May 19:S0090-8258(22)00305-5. doi: 10.1016/j.ygyno.2022.05.005. Epub ahead of print.
    • Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    • Mekonnen N, Yang H, Shin YK.
    • Front Oncol. 2022 May 18;12:880643. doi: 10.3389/fonc.2022.880643.
    • Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
    • Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, Van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC.
    • Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124. Epub ahead of print.
    • Comparative efficacy and safety of poly (ADP-ribose) polymerase inhibitors in patients with ovarian cancer : a systematic review and network meta-analysis.
    • Luo J, Ou S, Wei H, Qin X, Jiang Q.
    • Front Oncol. 2022 May 17;12:815265. doi: 10.3389/fonc.2022.815265.
    • Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    • Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, Shen Y, Wu X, Shao Y, Bao H, Wu X.
    • BMC Cancer. 2022 May 16;22(1):550. doi: 10.1186/s12885-022-09602-4.
    • Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.
    • Witjes VM, Braspenning JCC, Hoogerbrugge N, Smolders YHCM, Hermkens DMA, Mourits MJE, Ligtenberg MJL, Ausems MGEM, de Hullu JA.
    • Fam Cancer. 2022 May 16. doi: 10.1007/s10689-022-00294-0. Epub ahead of print.
    • State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    • Hinchcliff E, Westin SN, Herzog TJ.
    • Gynecol Oncol. 2022 May 16:S0090-8258(22)00275-X. doi: 10.1016/j.ygyno.2022.04.021. Epub ahead of print.
    • Review
    • The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    • Skelin M, Šarcevic D, Lešin Gacina D, Mucalo I, Dilber I, Javor E.
    • J Chemother. 2022 May 13:1-8. doi: 10.1080/1120009X.2022.2073161. Epub ahead of print.
    • Meta-Analysis
    • Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective.
    • Rose PG.
    • Cancer Drug Resist. 2022 May 12;5:415-423. doi: 10.20517/cdr.2022.01.
    • Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer.
    • Flynn MJ, Ledermann JA.
    • Cancer Drug Resist. 2022 May 12;5:424-435. doi: 10.20517/cdr.2022.13.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 May 3;32(5):639-645. doi: 10.1136/ijgc-2021-003116.
    • Clinical benefit of olaparib in Mexican ovarian cancer patients with founder mutation BRCA1-Del ex9-12.
    • Gallardo-Rincón D, Montes-Servín E, Alamilla-García G, Montes-Servín E, Bahena-González A, Cetina-Pérez L, Morales-Vásquez F, Cano-Blanco C, Coronel Martinez JA, González-Ibarra E, Espinoza-Romero R, Alvarez-Gómez RM, Pedroza-Torres A, Castro-Eguiluz D.
    • Front Genet. 2022 May 2;12:863956. doi: 10.3389/fgene.2022.863956.
    • A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    • Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team.
    • Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18.
    • A Review of MutSa and its Absence in Mismatch Repair Related Ovarian Carcinomas.
    • Hayes A, Jaman A, Johnson E, Rausch M.
    • FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R4038.
    • Conference abstract. Review
    • PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    • Miller RE, El-Shakankery KH, Lee JY.
    • J Gynecol Oncol. 2022 May;33(3):e44. doi: 10.3802/jgo.2022.33.e44. Epub 2022 Mar 8.
    • Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    • Lee JY, Kim BG, Kim JW, Lee JB, Park E, Joung JG, Kim S, Choi CH, Kim HS; Korean Gynecologic Oncology Group (KGOG) investigators.
    • J Gynecol Oncol. 2022 May;33(3):e45. doi: 10.3802/jgo.2022.33.e45. Epub 2022 Mar 4.

    Identifier: NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION). (ClinicalTrials.gov)

    • BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    • Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT.
    • Br J Cancer. 2022 Apr 30. doi: 10.1038/s41416-022-01823-5. Epub ahead of print.
    • The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.
    • Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, Behl S, Arcand SL, Nayar P, Spiegelman D, Gravel S, Mes-Masson AM, Provencher D, Foulkes WD, El Haffaf Z, Rouleau G, Bouchard L, Greenwood CMT, Masson JY, Ragoussis J, Tonin PN.
    • Cancers (Basel). 2022 Apr 30;14(9):2251. doi: 10.3390/cancers14092251.
    • Brain metastases in patients with ovarian cancer.
    • Limon D, Shachar E, Wolf I, Adar L, Peleg Hasson S, Ferro L, Safra T.
    • Acta Oncol. 2022 Apr 29:1-7. doi: 10.1080/0284186X.2022.2066985. Epub ahead of print.
    • Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature.
    • Zhang Z, Xu M, Sakandar A, Du X, He H, He W, Li D, Wen Q.
    • Front Oncol. 2022 Apr 29;12:873198. doi: 10.3389/fonc.2022.873198.
    • Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer.
    • Gou R, Horikawa N, Kosaka K.
    • BMJ Case Rep. 2022 Apr 20;15(4):e249177. doi: 10.1136/bcr-2022-249177.
    • Case report
    • Improving ovarian cancer treatment decision using a novel risk predictive tool.
    • Xu Z, Song J, Cao L, Rong Z, Zhang W, He J, Li K, Hou Y.
    • Aging (Albany NY). 2022 Apr 19;14(8):3464-3483. doi: 10.18632/aging.204023. Epub 2022 Apr 19.
    • A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.
    • Lee CS, Hernandez J, Liang C, Leung A, Stefanov DG, Cheng K, John V.
    • J Pharm Pract. 2022 Apr 19:8971900221088793. doi: 10.1177/08971900221088793. Epub ahead of print.
    • PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    • Luo L, Keyomarsi K.
    • Expert Opin Investig Drugs. 2022 Apr 18. doi: 10.1080/13543784.2022.2067527. Epub ahead of print.
    • Review
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    • Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L.
    • J Clin Oncol. 2022 Apr 11:JCO2101511. doi: 10.1200/JCO.21.01511. Epub ahead of print.

    Identifier: NCT03863860: A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
    • Weber-Lassalle K, Ernst C, Reuss A, Möllenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, Park-Simon TW, Hanker L, Prieske K, Schmidt S, Weber-Lassalle N, Pohl-Rescigno E, Kommoss S, Marmé F, Heitz F, Stingl JC, Schmutzler RK, Harter P, Hahnen E.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):565-570. doi: 10.1093/jnci/djab231.

    Commentary:

    Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies.

    • Templated insertions are associated specifically with BRCA2 deficiency and overall survival in advanced ovarian cancer.
    • Moore G, Majumdar R, Powell SN, Khan AJ, Weinhold N, Yin S, Higginson DS.
    • Mol Cancer Res. 2022 Apr 6:molcanres.MCR-21-1012-E.2021. doi: 10.1158/1541-7786.MCR-21-1012. Epub ahead of print.
    • Predicting Response to Anthracyclines in Ovarian Cancer.
    • Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N.
    • Int J Environ Res Public Health. 2022 Apr 2;19(7):4260. doi: 10.3390/ijerph19074260.
    • The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
    • Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, Baakza H, Wilson J, Ghilardi C, Cadogan EB, Giavazzi R, Bani MR.
    • Mol Cancer Ther. 2022 Apr 1;21(4):555-567. doi: 10.1158/1535-7163.MCT-21-0420.
    • The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    • Murphy AD, Morgan RD, Clamp AR, Jayson GC.
    • Br J Cancer. 2022 Apr;126(6):851-864. doi: 10.1038/s41416-021-01605-5. Epub 2021 Oct 29.
    • Review
    • Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    • Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI.
    • Br J Cancer. 2022 Apr;126(7):1027-1036. doi: 10.1038/s41416-021-01664-8. Epub 2021 Dec 9.
    • Immunotherapy for Ovarian Cancer.
    • Porter R, Matulonis UA.
    • Clin Adv Hematol Oncol. 2022 Apr;20(4):240-253.
    • An update on the safety of olaparib for treating ovarian cancer.
    • Cottrell K, Clark CL, Penson RT.
    • Expert Opin Drug Saf. 2022 Apr;21(4):447-451. doi: 10.1080/14740338.2022.2047176. Epub 2022 Mar 15.
    • Review
    • Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    • Vanderstichele A, Loverix L, Busschaert P, Van Nieuwenhuysen E, Han SN, Concin N, Callewaert T, Olbrecht S, Salihi R, Berteloot P, Neven P, Lambrechts D, Van Gorp T, Vergote I.
    • Gynecol Oncol. 2022 Apr;165(1):14-22. doi: 10.1016/j.ygyno.2022.01.034. Epub 2022 Feb 14.
    • Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    • Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E.
    • Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016/j.ygyno.2022.01.024. Epub 2022 Jan 31.
    • Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    • Wagar MK, Mojdehbakhsh RP, Godecker A, Rice LW, Barroilhet L.
    • Gynecol Oncol. 2022 Apr;165(1):49-52. doi: 10.1016/j.ygyno.2022.01.032. Epub 2022 Feb 8.
    • Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    • Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG, Lee JY.
    • Gynecol Oncol. 2022 Apr;165(1):97-104. doi: 10.1016/j.ygyno.2022.02.002. Epub 2022 Feb 10.
    • Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience.
    • Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, Heitz F.
    • Gynecol Oncol Rep. 2022 Feb 2 [eCollection 2022 Apr];40:100939. doi: 10.1016/j.gore.2022.100939.
    • Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
    • Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM.
    • Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14.

    Commentary:

    Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial.

    • Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.
    • Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, Wang J, Chen Y, Cheng Y, Wang Y, Lu W, Li W, Ma X, Hsu K.
    • Asia Pac J Clin Oncol. 2022 Mar 31. doi: 10.1111/ajco.13753. Epub ahead of print.
    • Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    • You B, Van Wagensveld L, Tod M, Sonke GS, Horlings HM, Kruitwagen RFPM, Du Bois A, Selle F, Perren T, Pfisterer J, Joly F, Cook A, Kaminsky MC, Wollschlaeger K, Lortholary A, Tome O, Leary A, Freyer G, Van Der Aa M, Colomban O.
    • Br J Cancer. 2022 Mar 31. doi: 10.1038/s41416-022-01732-7. Epub ahead of print.
    • PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    • Nicum S, Blagden SP.
    • Clin Cancer Res. 2022 Mar 31:clincanres.0442.2022. doi: 10.1158/1078-0432.CCR-22-0442. Epub ahead of print.
    • Commentary

    Original research:

    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).

    • The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
    • Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G, Maiello E.
    • Int J Mol Sci. 2022 Mar 31;23(7):3871. doi: 10.3390/ijms23073871.
    • Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    • Suh YJ, Lee B, Kim K, Jeong Y, Choi HY, Hwang SO, Kim YB.
    • BMC Cancer. 2022 Mar 30;22(1):346. doi: 10.1186/s12885-022-09455-x.
    • Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.
    • Harbin LM, Gallion HH, Allison DB, Kolesar JM.
    • Diagnostics (Basel). 2022 Mar 29;12(4):842. doi: 10.3390/diagnostics12040842.
    • A commentary on the discrepancy between blood and tumour BRCA testing: an open question.
    • De Paolis E, Marchetti C, Concolino P, Scambia G, Urbani A, Fagotti A, Minucci A.
    • BJOG. 2022 Mar 23. doi: 10.1111/1471-0528.17158. Epub ahead of print.
    • Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future-Five-Years' Single-Institution Experience of 762 Consecutive Patients.
    • Fumagalli C, Betella I, Rappa A, di Giminiani M, Gaiano M, De Vitis LA, Zambetti B, Vacirca D, Multinu F, Venetis K, Colombo N, Barberis M, Guerini Rocco E.
    • Cancers (Basel). 2022 Mar 23;14(7):1638. doi: 10.3390/cancers14071638.
    • Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.
    • Zhou D, Liu J, Liu R, Li H, Huang Y, Ma D, Hong L, Gao Q.
    • Front Oncol. 2022 Mar 23;12:852772. doi: 10.3389/fonc.2022.852772.

    Identifier: NCT04507841: Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer. (ClinicalTrials.gov)

    • Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
    • Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G.
    • Int J Gynecol Cancer. 2022 Mar 23:ijgc-2021-003009. doi: 10.1136/ijgc-2021-003009. Epub ahead of print.
    • Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    • Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S.
    • Int J Gynecol Cancer. 2022 Mar 22:ijgc-2022-003435. doi: 10.1136/ijgc-2022-003435. Epub ahead of print.
    • Study protocol

    Clinical Trials: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) (ClinicalTrials.gov)

    • Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
    • Li Y, Nie Y, Guo H, Guo H, Ha C, Li Y.
    • Front Oncol. 2022 Mar 18;12:847085. doi: 10.3389/fonc.2022.847085.
    • U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review.
    • Arora S, Narayan P, Ison G, Berman T, Suzman DL, Wedam S, Prowell TM, Ghosh S, Philip R, Osgood CL, Gao JJ, Shah M, Krol D, Wahby S, Royce M, Brus C, Bloomquist EW, Fiero MH, Tang S, Pazdur R, Ibrahim A, Amiri-Kordestani L, Beaver JA.
    • Clin Cancer Res. 2022 Mar 15;28(6):1058-1071. doi: 10.1158/1078-0432.CCR-21-2599.
    • Review
    • Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
    • Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA.
    • J Clin Oncol. 2022 Mar 15:JCO2102011. doi: 10.1200/JCO.21.02011. Epub ahead of print.
    • BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    • Godin P, Duhoux FP, Mazzeo F, Rojas M, Bollue E, François A, Galant C, Coulie J, Coyette M, Lentini A, Deswisen Y, Perlepe V, Fellah L, Leconte I, Berlière M.
    • Case Rep Oncol. 2022 Mar 14;15(1):238-244. doi: 10.1159/000521840.
    • PARP Inhibitors Resistance: Mechanisms and Perspectives.
    • Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D.
    • Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420.
    • Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing.
    • Stegel V, Blatnik A, Škof E, Dragoš VŠ, Krajc M, Gregoric B, Škerl P, Strojnik K, Klancar G, Banjac M, Žgajnar J, Ravnik M, Novakovic S.
    • Cancers (Basel). 2022 Mar 10;14(6):1434. doi: 10.3390/cancers14061434.
    • Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer.
    • Wei Q, Chen DS, Liu YH.
    • Front Oncol. 2022 Mar 10;12:853211. doi: 10.3389/fonc.2022.853211.
    • Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review.
    • Fujitsuka S, Horikawa N, Yoshida T, Yu S, Kuroda R, Tsuji M, Umemiya M, Gou R, Inayama Y, Tani H, Kosaka K.
    • Case Rep Oncol. 2022 Mar 3;15(1):156-162. doi: 10.1159/000522153.
    • Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • Lorusso D, Guy H, Samyshkin Y, Hawkes C, Estenson K, Coleman RL.
    • Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285.
    • Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer.
    • Chen Q, Li X, Zhang Z, Wu T.
    • Front Oncol. 2022 Mar 1;12:858826. doi: 10.3389/fonc.2022.858826.
    • European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
    • Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R, Lambrechts D; European experts’ consensus group.
    • Ann Oncol. 2022 Mar;33(3):276-287. doi: 10.1016/j.annonc.2021.11.013. Epub 2021 Dec 1.

    Commentary:

    Homologous recombination deficiency testing in first-line ovarian cancer.

    • Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    • Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E.
    • Gynecol Oncol. 2022 Mar;164(3):498-504. doi: 10.1016/j.ygyno.2021.12.025. Epub 2022 Jan 19.
    • A review on mechanisms of resistance to PARP inhibitors.
    • Desai C, Pathak A, Limaye S, Maniar V, Joshi A.
    • Indian J Cancer. 2022 Mar;59(Supplement):S119-S129. doi: 10.4103/ijc.IJC_53_21.
    • A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    • Park J, Lim MC, Lee JK, Jeong DH, Kim SI, Choi MC, Kim BG, Lee JY.
    • J Gynecol Oncol. 2022 Mar;33(2):e12. doi: 10.3802/jgo.2022.33.e12. Epub 2021 Dec 6.
    • Major clinical research advances in gynecologic cancer in 2021.
    • Park JY, Lee JY, Lee YY, Shim SH, Suh DH, Kim JW.
    • J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43.
    • The BRCA Gene in Epithelial Ovarian Cancer.
    • Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, Patiño-García A, González-Martín A.
    • Cancers (Basel). 2022 Feb 27;14(5):1235. doi: 10.3390/cancers14051235.
    • Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer.
    • Maity J, Horibata S, Zurcher G, Lee JM.
    • Cancers (Basel). 2022 Feb 26;14(5):1219. doi: 10.3390/cancers14051219.
    • Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.
    • Qian B, Leng W, Yan Z, Lu J, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Feb 25;12:778545. doi: 10.3389/fonc.2022.778545.
    • The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    • Francis KE, Kim SI, Friedlander M, Gebski V, Coquard IR, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK.
    • Ann Oncol. 2022 Feb 24:S0923-7534(22)00338-6. doi: 10.1016/j.annonc.2022.02.222. Epub ahead of print.
    • Sophia Genetics, AstraZeneca Team on In-House HRD Testing in Ovarian Cancer.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2022 Feb 24.
    • Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives.
    • Musacchio L, Cicala CM, Salutari V, Camarda F, Carbone MV, Ghizzoni V, Giudice E, Nero C, Perri MT, Ricci C, Tronconi F, Scambia G, Lorusso D.
    • Front Oncol. 2022 Feb 23;12:831612. doi: 10.3389/fonc.2022.831612.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J.
    • Cochrane Database Syst Rev. 2022 Feb 16;2:CD007929. doi: 10.1002/14651858.CD007929.pub4.
    • Review
    • Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    • Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, Zhou Q, Zhang S, Wang D, Shi H, Gao Y, Huang Y, Li G, Wang X, Cheng Y, Lou G, Gao Q, Wang L, Du X, Pan M, Mu X, Li L, Li M, Mu S, Kong B.
    • Clin Cancer Res. 2022 Feb 15;28(4):653-661. doi: 10.1158/1078-0432.CCR-21-1186.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
    • Nie X, Chen X, Jiang Y, Zhong Y, Chen T, Cheng W.
    • Medicine (Baltimore). 2022 Feb 11;101(6):e28712. doi: 10.1097/MD.0000000000028712.
    • Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.
    • Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI.
    • JCO Precis Oncol. [2022 Feb 9];6:e2100456. doi: 10.1200/PO.21.00456.
    • Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    • Gao Q, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Low J, Kong B, Rozita AM, Sen LC, Yin R, Xie X, Liu J, Sun W, Su J, Zhang C, Zang R, Ma D.
    • Clin Cancer Res. 2022 Feb 7:clincanres.3023.2021. doi: 10.1158/1078-0432.CCR-21-3023. Epub ahead of print.

    Commentary:

    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.

    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    • Perez JM, Twigg CAI, Guan W, Thomas SN.
    • J Am Soc Mass Spectrom. 2022 Feb 2;33(2):242-250. doi: 10.1021/jasms.1c00215. Epub 2021 Dec 27.
    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.
    • Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.
    • Imyanitov EN, Iyevleva AG.
    • Cancer Lett. 2022 Feb 1;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.
    • Review
    • Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
    • Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW.
    • Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2117754119. doi: 10.1073/pnas.2117754119.

    Commentary:

    Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

    • 11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.
    • van Halteren HK, Tan A, Pellegrino B, Brasiuniene B, Bennouna J, Cunquero-Tomás AJ, Strijbos M; ESMO Practicing Oncologists Working Group.
    • ESMO Open. 2022 Feb;7(1):100376. doi: 10.1016/j.esmoop.2021.100376. Epub 2022 Jan 17.
    • Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    • Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, Monberg M, Szamreta EA, Amin S, McLaurin K.
    • Future Oncol. 2022 Feb;18(4):491-503. doi: 10.2217/fon-2021-0567. Epub 2021 Dec 8.
    • Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    • Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL.
    • Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.

    Commentary:

    Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?

    Podcast:

    February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?

    • Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    • Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL.
    • Gynecol Oncol. 2022 Feb;164(2):278-287. doi: 10.1016/j.ygyno.2021.12.012. Epub 2021 Dec 18.
    • Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    • Moya-Alarcón C, González-Domínguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta MP, Pérez-Fidalgo JA, Redondo A.
    • Gynecol Oncol. 2022 Feb;164(2):406-414. doi: 10.1016/j.ygyno.2021.11.011. Epub 2021 Nov 26.
    • Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    • Ha HI, Park EY, Eoh KJ, Lee YJ, Seo SS, Kang S, Park SY, Lim MC.
    • Gynecol Oncol. 2022 Feb;164(2):415-420. doi: 10.1016/j.ygyno.2021.12.013. Epub 2021 Dec 17.
    • PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.
    • Kraya AA, Maxwell KN, Eiva MA, Wubbenhorst B, Pluta J, Feldman M, Nayak A, Powell DJ Jr, Domchek SM, Vonderheide RH, Nathanson KL.
    • JCO Precis Oncol. 2022 Feb;6:e2100159. doi: 10.1200/PO.21.00159.
    • Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.
    • Pirš B, Škof E, Smrkolj V, Smrkolj Š.
    • Cancers (Basel). 2022 Jan 27;14(3):631. doi: 10.3390/cancers14030631.
    • Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.
    • Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, Rojas K, Morales L, Wang S, Han X, Dueñas M, Paramio JM, Manso L.
    • NPJ Precis Oncol. 2022 Jan 27;6(1):7. doi: 10.1038/s41698-021-00247-3.
    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    • Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM.
    • Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22.
    • Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report.
    • Cortesi L, Venturelli M, Barbieri E, Baldessari C, Bardasi C, Coccia E, Baglio F, Rimini M, Greco S, Napolitano M, Pipitone S, Dominici M.
    • Ther Adv Chronic Dis. 2022 Jan 13;13:20406223211063023. doi: 10.1177/20406223211063023.
    • Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Pagkali A, Mamais I, Michalinos A, Agouridis AP.
    • Curr Oncol. 2022 Jan 12;29(1):321-336. doi: 10.3390/curroncol29010029.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
    • Ni J, Guo W, Zhao Q, Cheng X, Xu X, Zhou R, Gu H, Chen C, Chen X.
    • Front Oncol. 2022 Jan 6;11:746571. doi: 10.3389/fonc.2021.746571.
    • Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study.
    • Fu M, Jin C, Feng S, Jia Z, Nie L, Zhang Y, Peng J, Wang X, Bu H, Kong B.
    • Front Oncol. 2022 Jan 6;11:810099. doi: 10.3389/fonc.2021.810099.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    • Park SJ, Chang SJ, Suh DH, Kong TW, Song H, Kim TH, Kim JW, Kim HS, Lee SJ.
    • BMC Cancer. 2022 Jan 3;22(1):28. doi: 10.1186/s12885-021-09138-z.
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    • Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G.
    • Br J Cancer. 2022 Jan;126(1):120-128. doi: 10.1038/s41416-021-01609-1. Epub 2021 Nov 3.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • As Maintenance Therapy, Olaparib's Benefits Continue.
    • [No author given]
    • Cancer Discov. 2022 Jan;12(1):6-7. doi: 10.1158/2159-8290.CD-NB2021-0401. Epub 2021 Nov 19.
    • Research news

    Original research:

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

    • Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients.
    • Moya-Alarcón C, Piera G, Callejo Á, Gascó A.
    • J Comp Eff Res. 2022 Jan;11(1):13-27. doi: 10.2217/cer-2021-0135. Epub 2021 Oct 26.
    • Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
    • Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M; HyNOVA Protocol Steering Committee.
    • J Gynecol Oncol. 2022 Jan;33(1):e1. doi: 10.3802/jgo.2022.33.e1. Epub 2021 Oct 18.
    • Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
    • Ghirardi V, De Felice F, D'Indinosante M, Bernardini F, Giudice MT, Fagotti A, Scambia G.
    • Cancer Treat Res Commun. 2022;31:100518. doi: 10.1016/j.ctarc.2022.100518. Epub 2022 Jan 14.
    • Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.
    • Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB, Romero C.
    • Biomedicines. 2021 Dec 31;10(1):77. doi: 10.3390/biomedicines10010077.
    • DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
    • Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A.
    • Biomedicines. 2021 Dec 31;10(1):82. doi: 10.3390/biomedicines10010082.
    • Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    • Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, Orsulic S, Karlan BY, Svendsen CN.
    • Cell Rep. 2021 Dec 28;37(13):110146. doi: 10.1016/j.celrep.2021.110146.

    Research news: Researchers Create Organoids that Model BRCA-Positive Ovarian Cancer. (Clinical OMICs)

    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    • Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, Burney I.
    • BMC Cancer. 2021 Dec 20;21(1):1350. doi: 10.1186/s12885-021-09094-8.
    • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
    • Zhang M, Ma SC, Tan JL, Wang J, Bai X, Dong ZY, Zhang QX.
    • Front Oncol. 2021 Dec 16;11:772604. doi: 10.3389/fonc.2021.772604.
    • Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.
    • Bonadio RC, Estevez-Diz MDP.
    • Front Oncol. 2021 Dec 15;11:754524. doi: 10.3389/fonc.2021.754524.
    • Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study).
    • Liontos M, Timotheadou E, Papadopoulos EI, Zafeiriou Z, Lampropoulou DI, Aravantinos G, Mavroudis D, Christodoulou C, Nikolaidi A, Somarakis A, Papadimitriou C, Papandreou C, Bamias A.
    • Curr Oncol. 2021 Dec 10;28(6):5266-5277. doi: 10.3390/curroncol28060440.
    • Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
    • Zhang JQ, Zhao BB, Wang MM, Li L.
    • Front Oncol. 2021 Dec 6;11:603591. doi: 10.3389/fonc.2021.603591.
    • Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
    • Scotto G, Borella F, Turinetto M, Tuninetti V, Valsecchi AA, Giannone G, Cosma S, Benedetto C, Valabrega G.
    • Cells. 2021 Dec 3;10(12):3408. doi: 10.3390/cells10123408.
    • Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer.
    • Joly F, Ray-Coquard I.
    • Bull Cancer. 2021 Dec;108(9S1):S1-S4. French. doi: 10.1016/S0007-4551(21)00581-6.
    • Guideline, [Article in French]
    • Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
    • Selle F, Alexandre J, Prulhière K, Kalbacher E, Ray-Coquard I, Leary A; pour le groupe GINECO.
    • Bull Cancer. 2021 Dec;108(9S1):S5-S12. doi: 10.1016/S0007-4551(21)00582-8.
    • Guideline
    • Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
    • Pautier P, Motte-Rouge T, Lécuru F, Classe JM, Ferron G, Floquet A, Kurtz JE, Freyer G, Hardy-Bessard AC.
    • Bull Cancer. 2021 Dec;108(9S1):S22-S32. doi: 10.1016/S0007-4551(21)00584-1.
    • Guideline
    • Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    • Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA.
    • Gynecol Oncol. 2021 Dec;163(3):490-497. doi: 10.1016/j.ygyno.2021.08.030. Epub 2021 Sep 30.
    • Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    • Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
    • Gynecol Oncol. 2021 Dec;163(3):498-505. doi: 10.1016/j.ygyno.2021.09.012. Epub 2021 Oct 1.
    • Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    • Hodgson DR, Brown JS, Dearden SP, Lai Z, Elks CE, Milenkova T, Dougherty BA, Lanchbury JS, Perry M, Timms KM, Harrington EA, Barrett JC, Leary A, Pujade-Lauraine E.
    • Gynecol Oncol. 2021 Dec;163(3):563-568. doi: 10.1016/j.ygyno.2021.10.002. Epub 2021 Nov 4.
    • ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
    • Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS.
    • Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30.
    • Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P.
    • Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26. Erratum in: Lancet Oncol. 2021 Dec;22(12):e539.

    Research news:

    As Maintenance Therapy, Olaparib's Benefits Continue.

    • BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    • Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse SA.
    • Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108. Epub 2021 Oct 12.
    • Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
    • Klotz DM, Link T, Wimberger P, Kuhlmann JD.
    • Mol Oncol. 2021 Dec;15(12):3626-3638. doi: 10.1002/1878-0261.12949. Epub 2021 Apr 2.
    • Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
    • Dias MP, Moser SC, Ganesan S, Jonkers J.
    • Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
    • Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    • Xu Q, Li Z.
    • Front Pharmacol. 2021 Nov 29;12:743073. doi: 10.3389/fphar.2021.743073.
    • Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Wang H, Wu M, Liu H, Zhou H, Zhao Y, Geng Y, Jiang B, Zhang K, Zhang B, Han Z, Du X.
    • Front Oncol. 2021 Nov 24;11:785102. doi: 10.3389/fonc.2021.785102.
    • Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
    • DiSilvestro P, Colombo N, Harter P, González-Martín A, Ray-Coquard I, Coleman RL.
    • Cancers (Basel). 2021 Nov 17;13(22):5756. doi: 10.3390/cancers13225756.
    • Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    • Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.
    • Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.
    • Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer.
    • Gao L, Chen R, Li T, Li L, Zheng Q.
    • Front Pharmacol. 2021 Nov 8;12:771836. doi: 10.3389/fphar.2021.771836.
    • VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
    • Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R.
    • J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x.
    • Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases.
    • Santos P, Imber BS, Lapen K, Pike LRG, Moss N, Seidman AD, Beal K.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e605. doi: 10.1016/j.ijrobp.2021.07.1614.
    • Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    • Moore KN, Pothuri B.
    • Cancer J. 2021 Nov-Dec 01;27(6):432-440. doi: 10.1097/PPO.0000000000000558.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    • Pham MM, Hinchcliff E, Avila M, Westin SN.
    • Cancer J. 2021 Nov-Dec 01;27(6):491-500. doi: 10.1097/PPO.0000000000000562.
    • Review
    • Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
    • Miller RE.
    • Cancer J. 2021 Nov-Dec 01;27(6):506-510. doi: 10.1097/PPO.0000000000000565.
    • Review
    • The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
    • You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E.
    • Cancer Treat Rev. 2021 Nov;100:102294. doi: 10.1016/j.ctrv.2021.102294. Epub 2021 Sep 15.
    • Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
    • Matsuo K, Klar M, Mohrbacher AF, Roman LD, Wright JD.
    • Eur J Cancer. 2021 Nov;157:59-62. doi: 10.1016/j.ejca.2021.08.016. Epub 2021 Sep 3.
    • Letter
    • Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    • Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P.
    • Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28.
    • Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.
    • Westin SN, Louie-Gao M, Gupta D, Thaker PH.
    • Future Oncol. 2021 Nov;17(32):4263-4274. doi: 10.2217/fon-2021-0018. Epub 2021 Aug 11.
    • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    • Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F.
    • Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5.
    • Adherence to PARP inhibitor therapy among women with ovarian cancer.
    • Moss HA, Chen L, Hershman DL, Davidson B, Wright JD.
    • Gynecol Oncol. 2021 Nov;163(2):262-268. doi: 10.1016/j.ygyno.2021.08.025. Epub 2021 Sep 9.
    • Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    • Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.
    • Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.
    • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer.
    • Navitski A, Al-Rawi DH, Liu Y, Rubinstein MM, Friedman CF, Rampal RK, Mandelker DL, Cadoo K, O'Cearbhaill RE.
    • Gynecol Oncol Rep. 2021 Oct 5;38:100873. doi: 10.1016/j.gore.2021.100873. eCollection 2021 Nov.
    • Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020.
    • Obermair A, Beale P, Scott CL, Beshay V, Kichenadasse G, Simcock B, Nicklin J, Lee YC, Cohen P, Meniawy T.
    • J Gynecol Oncol. 2021 Nov;32(6):e95. doi: 10.3802/jgo.2021.32.e95.
    • Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    • Paik J.
    • Target Oncol. 2021 Nov;16(6):847-856. doi: 10.1007/s11523-021-00842-1. Epub 2021 Oct 8.
    • Review
    • Homologous recombination proficiency in ovarian and breast cancer patients.
    • Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.
    • BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.
    • BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.
    • Li S, Tao L, Dai H, Gong X, Zhuo Y, Xiang H, Zhao Y, Gao Q, Deng L.
    • Front Oncol. 2021 Oct 28;11:718871. doi: 10.3389/fonc.2021.718871.
    • PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
    • Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E.
    • Cancers (Basel). 2021 Oct 27;13(21):5380. doi: 10.3390/cancers13215380.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    • Mehta P, Bothra SJ.
    • Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23.
    • Review. Book chapter
    • Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    • Trédan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, Hardy-Bessard AC, Kalbacher E, Floquet A, Venat-Bouvet L, Lortholary A, Pop O, Frenel JS, Cancel M, Largillier R, Louvet C, You B, Zannetti A, Anota A, Treilleux I, Pissaloux D, Houlier A, Savoye AM, Mouret-Reynier MA, Meunier J, Levaché CB, Brocard F, Ray-Coquard I.
    • Gynecol Oncol. 2021 Oct 22:S0090-8258(21)01402-5. doi: 10.1016/j.ygyno.2021.09.024. Epub ahead of print.
    • Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer.
    • Drouin L, Guani B, Balaya V, Azaïs H, Betrian S, Bolze PA, Dabi Y, Kerbage Y, Sanson C, Zaccarini F, Mathevet P, Lécuru F, Guyon F, Akladios C, Bendifallah S, Deluche E, On Behalf Of The Sfog Campus Young Of French Society Of Gynecological Oncology.
    • J Clin Med. 2021 Oct 21;10(21):4829. doi: 10.3390/jcm10214829.
    • Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing.
    • Wessman S, Fuentes BB, Törngren T, Kvist A, Kokaraki G, Menkens H, Hjerpe E, Hugo Y, Petta TB, Borg Å, Carlson JW.
    • Cancers (Basel). 2021 Oct 19;13(20):5240. doi: 10.3390/cancers13205240.
    • Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.
    • Wong OGW, Li J, Cheung ANY.
    • Front Oncol. 2021 Oct 19;11:666815. doi: 10.3389/fonc.2021.666815.
    • Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
    • Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN.
    • Br J Cancer. 2021 Oct 18. doi: 10.1038/s41416-021-01560-1. Epub ahead of print.
    • A Retrospective Cross-Sectional Cohort Trial Assessing the Prevalence of MTHFR Polymorphisms and the Influence of Diet on Platinum Resistance in Ovarian Cancer Patients.
    • Phillips-Chavez C, Coward J, Watson M, Schloss J.
    • Cancers (Basel). 2021 Oct 18;13(20):5215. doi: 10.3390/cancers13205215.
    • Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    • Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F, Desai S, McGrail JC, Taylor SS.
    • J Exp Clin Cancer Res. 2021 Oct 16;40(1):323. doi: 10.1186/s13046-021-02124-0.
    • Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
    • Sztupinszki Z, Diossy M, Börcsök J, Prosz A, Cornelius N, Kjeldsen MK, Mirza MR, Szallasi Z.
    • Clin Cancer Res. 2021 Oct 15;27(20):5681-5687. doi: 10.1158/1078-0432.CCR-21-0981. Epub 2021 Aug 11.
    • Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    • Chiang YC, Lin PH, Cheng WF.
    • Front Oncol. 2021 Oct 14;11:675972. doi: 10.3389/fonc.2021.675972.
    • Ovarian Cancer With Breast Metastasis and Two Pathogenic Variants of BRCA1 Gene.
    • Kowsarnia S, Javadi N.
    • Cureus. 2021 Oct 11;13(10):e18691. doi: 10.7759/cureus.18691.
    • Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
    • Tang YH, Lin CY, Lai CH.
    • Genes (Basel). 2021 Oct 9;12(10):1593. doi: 10.3390/genes12101593.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    • Zavarikina TM, Khokhlova SV, Tyulyandina AS, Khabas GN, Asaturova AV, Nosova YV, Brenner PK, Kapralova MA, Khodirev DS, Stenina MB.
    • Bull Exp Biol Med. 2021 Oct;171(6):755-759. doi: 10.1007/s10517-021-05310-4. Epub 2021 Oct 28.
    • PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    • Wethington SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, Karlan BY, Fader AN, Dowdy SC.
    • Gynecol Oncol. 2021 Oct;163(1):11-13. doi: 10.1016/j.ygyno.2021.08.002. Epub 2021 Aug 12.
    • Commentary
    • Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    • Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    • Gynecol Oncol. 2021 Oct;163(1):41-49. doi: 10.1016/j.ygyno.2021.07.016. Epub 2021 Aug 2.
    • Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
    • Liu J, Hawkes C, Walder L, Spalding C, Travers K, Maiese EM, Hurteau J.
    • J Manag Care Spec Pharm. 2021 Oct;27(10):1377-1387. doi: 10.18553/jmcp.2021.27.10.1377.
    • Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status.
    • Rolfe M, Gegeckas C, Turner S, Orr JW Jr.
    • J Oncol Pharm Pract. 2021 Oct;27(7):1704-1709. doi: 10.1177/1078155220967988. Epub 2020 Oct 25.
    • Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    • Barbosa A, Pinto P, Peixoto A, Guerra J, Pinheiro M, Santos C, Pinto C, Escudeiro C, Bartosch C, Santos R, Brandão A, Silva J, Teixeira MR.
    • Front Oncol. 2021 Sep 30;11:754094. doi: 10.3389/fonc.2021.754094.
    • Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.
    • Hayward SB, Ciccia A.
    • Curr Opin Genet Dev. 2021 Sep 25;71:171-181. doi: 10.1016/j.gde.2021.08.006. Epub ahead of print.
    • Review
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
    • Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL.
    • Cancer Med. 2021 Sep 21. doi: 10.1002/cam4.4260. Epub ahead of print.
    • Role of adjuvant and post-surgical treatment in gynaecological cancer.
    • Ngu SF, Ngan HY, Chan KK.
    • Best Pract Res Clin Obstet Gynaecol. 2021 Sep 15:S1521-6934(21)00124-3. doi: 10.1016/j.bpobgyn.2021.09.001. Epub ahead of print.
    • Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells.
    • Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, Mirshahidi S, Ioffe YJ, Unternaehrer JJ.
    • Cancers (Basel). 2021 Sep 15;13(18):4617. doi: 10.3390/cancers13184617.
    • Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    • Saravi S, Alizzi Z, Tosi S, Hall M, Karteris E.
    • Cells. 2021 Sep 15;10(9):2434. doi: 10.3390/cells10092434.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
    • Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP.
    • JCO Precis Oncol. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439.
    • Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.
    • Ni J, Cheng X, Zhou R, Zhao Q, Xu X, Guo W, Gu H, Chen C, Chen X.
    • Front Oncol. 2021 Sep 6;11:724620. doi: 10.3389/fonc.2021.724620.
    • Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
    • Lai J, Tong C, Chien JR.
    • Anticancer Res. 2021 Sep;41(9):4417-4422. doi: 10.21873/anticanres.15248.
    • Case report
    • Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    • Rasmussen M, Lim K, Rambech E, Andersen MH, Svane IM, Andersen O, Jensen LH, Nilbert M, Therkildsen C.
    • Gynecol Oncol. 2021 Sep;162(3):686-693. doi: 10.1016/j.ygyno.2021.07.001. Epub 2021 Jul 16.
    • Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases.
    • Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A.
    • Int J Gynecol Cancer. 2021 Sep;31(9):1292-1296. doi: 10.1136/ijgc-2020-002225.
    • Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
    • Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I.
    • J Gynecol Oncol. 2021 Sep;32(5):e82. doi: 10.3802/jgo.2021.32.e82.
    • Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
    • Mani C, Tripathi K, Chaudhary S, Somasagara RR, Rocconi RP, Crasto C, Reedy M, Athar M, Palle K.
    • Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
    • Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
    • Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE.
    • NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.
    • Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
    • Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.
    • Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.
    • Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B.
    • Curr Oncol. 2021 Aug 24;28(5):3227-3239. doi: 10.3390/curroncol28050280.
    • Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay.
    • Nikoleousakos N, Dalezis P, Polonifi A, Geromichalou EG, Sagredou S, Alifieris CE, Deligiorgi MV, Sarli V, Trafalis DT.
    • Biomedicines. 2021 Aug 17;9(8):1028. doi: 10.3390/biomedicines9081028.
    • Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.
    • Velev M, Puszkiel A, Blanchet B, de Percin S, Delanoy N, Medioni J, Gervais C, Balakirouchenane D, Khoudour N, Pautier P, Leary A, Ajgal Z, Hirsch L, Goldwasser F, Alexandre J, Beinse G.
    • Pharmaceuticals (Basel). 2021 Aug 16;14(8):804. doi: 10.3390/ph14080804.
    • Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M.
    • Front Oncol. 2021 Aug 13;11:638295. doi: 10.3389/fonc.2021.638295.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    • Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, Morrow M, Berek JS, Hofer TP, Katz SJ, Ward KC.
    • J Natl Cancer Inst. 2021 Aug 9:djab151. doi: 10.1093/jnci/djab151. Epub ahead of print.
    • PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
    • Dickson KA, Xie T, Evenhuis C, Ma Y, Marsh DJ.
    • Int J Mol Sci. 2021 Aug 7;22(16):8506. doi: 10.3390/ijms22168506.
    • Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
    • Kim SI, Lee JW, Kim K, Lee M, Yoo J, Choi MC, Hwangbo S, Kwak YH, Lee JM, Shin SJ, Shim SH, Kim MK.
    • J Gynecol Oncol. 2021 Aug 5. doi: 10.3802/jgo.2021.32.e90. Epub ahead of print.
    • Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Aug 3.
    • Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    • Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr.
    • Gynecol Oncol. 2021 Aug;162(2):345-352. doi: 10.1016/j.ygyno.2021.05.015. Epub 2021 May 25.
    • Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    • Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF.
    • Gynecol Oncol. 2021 Aug;162(2):482-495. doi: 10.1016/j.ygyno.2021.05.018. Epub 2021 Jun 3.
    • Review
    • Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
    • Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L.
    • Gynecol Oncol. 2021 Aug;162(2):496-505. doi: 10.1016/j.ygyno.2021.05.012. Epub 2021 May 19.
    • Meta-Analysis
    • Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    • Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
    • Cancer Res. 2021 Jul 28:canres.0774.2021. doi: 10.1158/0008-5472.CAN-21-0774. Epub ahead of print.
    • Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    • Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A.
    • ESMO Open. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212. Epub ahead of print.
    • Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
    • Imyanitov E, Sokolenko A.
    • World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.
    • Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    • Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L, Pavone M, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00587-4. doi: 10.1016/j.ygyno.2021.07.025. Epub ahead of print.
    • Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    • Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    • Exp Cell Res. 2021 Jul 21:112742. doi: 10.1016/j.yexcr.2021.112742. Epub ahead of print.
    • Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    • Moss HA, Perhanidis JA, Havrilesky LJ, Secord AA.
    • Gynecol Oncol. 2021 Jul 20:S0090-8258(21)00588-6. doi: 10.1016/j.ygyno.2021.07.026. Epub ahead of print.
    • Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
    • Tjokrowidjaja A, Friedlander M, Lord SJ, Asher R, Rodrigues M, Ledermann JA, Matulonis UA, Oza AM, Bruchim I, Huzarski T, Gourley C, Harter P, Vergote I, Scott CL, Meier W, Shapira-Frommer R, Milenkova T, Pujade-Lauraine E, Gebski V, Lee CK.
    • Eur J Cancer. 2021 Jul 19;154:190-200. doi: 10.1016/j.ejca.2021.06.024. Epub ahead of print.
    • Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis.
    • Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M.
    • Front Oncol. 2021 Jul 19;10:638295. doi: 10.3389/fonc.2021.638295.
    • Clinical biomarkers predicting the therapeutic effect of olaparib on platinum-sensitive recurrent ovarian cancer patients with unknown germline BRCA mutations.
    • Nakanishi K, Yamada T, Ishikawa G, Suzuki S.
    • Front Oncol. 2021 Jul 19;10:697952. doi: 10.3389/fonc.2021.697952.
    • Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    • De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R.
    • Gynecol Oncol. 2021 Jul 19:S0090-8258(21)00581-3. doi: 10.1016/j.ygyno.2021.07.019. Epub ahead of print.
    • Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    • Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee.
    • Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.
    • Meta-Analysis
    • PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
    • Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, Ray-Coquard I.
    • Cancer Treat Rev. 2021 Jul 15;99:102255. doi: 10.1016/j.ctrv.2021.102255. Epub ahead of print.
    • Review
    • Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
    • Raimundo L, Calheiros J, Saraiva L.
    • Cancers (Basel). 2021 Jul 9;13(14):3438. doi: 10.3390/cancers13143438.
    • Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
    • Leung JH, Lang HC, Wang SY, Lo HF, Chan AL.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Jul 9. doi: 10.1080/14737167.2021.1954506. Epub ahead of print.
    • Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
    • Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH.
    • NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028.
    • Melphalan as a promising treatment for BRCA-related ovarian carcinoma.
    • Conteduca V, Scarpi E, Farolfi A, Brighi N, Rossi L, Gurioli G, Lolli C, Schepisi G, Bleve S, Gianni C, Virga A, Altavilla A, Burgio SL, Menna C, De Giorgi U.
    • Front Oncol. 2021 Jul 6;10:716467. doi: 10.3389/fonc.2021.716467.
    • Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
    • Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA.
    • Am J Obstet Gynecol. 2021 Jul;225(1):68.e1-68.e11. doi: 10.1016/j.ajog.2021.01.029. Epub 2021 Feb 4.
    • Multimodal Treatment of Primary Advanced Ovarian Cancer.
    • Friedrich M, Friedrich D, Kraft C, Rogmans C.
    • Anticancer Res. 2021 Jul;41(7):3253-3260. doi: 10.21873/anticanres.15111. Epub 2021 Jul 5.
    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Jul;125(1):7-14. doi: 10.1038/s41416-021-01295-z. Epub 2021 Mar 25.
    • Commentary, Review
    • Pamiparib: First Approval.
    • Markham A.
    • Drugs. 2021 Jul;81(11):1343-1348. doi: 10.1007/s40265-021-01552-8.
    • Review
    • BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    • Royfman R, Whiteley E, Noe O, Morand S, Creeden J, Stanbery L, Hamouda D, Nemunaitis J.
    • Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
    • Review
    • Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan.
    • Hsu CC, Pan YB, Lai CH, Chang TC, Yang LY, Chou HH.
    • Taiwan J Obstet Gynecol. 2021 Jul;60(4):634-638. doi: 10.1016/j.tjog.2021.05.010.
    • Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer.
    • Sanders BE, Ku L, Walker P, Bitler BG.
    • Technol Cancer Res Treat. 2021 Jan-Dec [First Published June 25, 2021.];20:15330338211027917. doi: 10.1177/15330338211027917.
    • The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
    • Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E.
    • Cancers (Basel). 2021 Jun 23;13(13):3136. doi: 10.3390/cancers13133136.
    • Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
    • Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B.
    • Biomedicines. 2021 Jun 22;9(7):706. doi: 10.3390/biomedicines9070706.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.
    • Muggia F, Bonetti A.
    • Cancer Drug Resist. 2021 Jun 19;4(2):453-462. doi: 10.20517/cdr.2020.116.
    • Ovarian Cancer: Biomarkers and Targeted Therapy.
    • Radu MR, Pradatu A, Duica F, Micu R, Cretoiu SM, Suciu N, Cretoiu D, Varlas VN, Radoi VE.
    • Biomedicines. 2021 Jun 18;9(6):693. doi: 10.3390/biomedicines9060693.
    • Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.
    • Shen J, Liu T, Bei Q, Xu S.
    • Front Oncol. 2021 Jun 17;11:685065. doi: 10.3389/fonc.2021.685065.
    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors.
    • Do K, Kochupurakkal BS, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2021 Jun 15:clincanres.1279.2021. doi: 10.1158/1078-0432.CCR-21-1279. Epub ahead of print.
    • Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
    • Romero I, López-Guerrero JA, Pignata S.
    • Expert Rev Anticancer Ther. 2021 Jun 15. doi: 10.1080/14737140.2021.1941890. Epub ahead of print.
    • Review
    • Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
    • Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2021 Jun 15:ijgc-2021-002727. doi: 10.1136/ijgc-2021-002727. Epub ahead of print.
    • Fuzuloparib: First Approval.
    • Lee A.
    • Drugs. 2021 Jun 12. doi: 10.1007/s40265-021-01541-x. Epub ahead of print.
    • Review
    • Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
    • Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA.
    • Int J Gynecol Cancer. 2021 Jun 8:ijgc-2020-002240. doi: 10.1136/ijgc-2020-002240. Epub ahead of print.
    • Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    • Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL.
    • Gynecol Oncol. 2021 Jun 7:S0090-8258(21)00437-6. doi: 10.1016/j.ygyno.2021.05.031. Epub ahead of print.
    • Advances in the Treatment of Platinum Resistant Epithelial Ovarian Cancer: an update on standard and experimental therapies.
    • Leung SOA, Konstantinopoulos PA.
    • Expert Opin Investig Drugs. 2021 Jun 4. doi: 10.1080/13543784.2021.1939305. Epub ahead of print.
    • Review
    • Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    • Sokolenko AP, Gorodnova TV, Bizin IV, Kuligina ES, Kotiv KB, Romanko AA, Ermachenkova TI, Ivantsov AO, Preobrazhenskaya EV, Sokolova TN, Broyde RV, Imyanitov EN.
    • Cancer Chemother Pharmacol. 2021 Jun 2. doi: 10.1007/s00280-021-04301-6. Epub ahead of print.
    • Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
    • Zhong Q, Xiong Y, Ling C, Qian Y, Zhao X, Yang H.
    • Exp Biol Med (Maywood). 2021 Jun;246(11):1297-1306. doi: 10.1177/1535370221994077.
    • Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
    • Le Saux O, Vanacker H, Guermazi F, Carbonnaux M, Roméo C, Larrouquère L, Trédan O, Ray-Coquard I.
    • Future Oncol. 2021 Jun;17(18):2291-2304. doi: 10.2217/fon-2021-0059. Epub 2021 Mar 17.
    • Review
    • Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
    • Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2021 Jun;161(3):653-659. doi: 10.1016/j.ygyno.2021.03.011. Epub 2021 Mar 15.
    • Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    • Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY.
    • Gynecol Oncol. 2021 Jun;161(3):762-768. doi: 10.1016/j.ygyno.2021.03.019. Epub 2021 Mar 24.
    • PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
    • Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J.
    • Redox Biol. 2021 Jun;42:101928. doi: 10.1016/j.redox.2021.101928. Epub 2021 Mar 5.
    • The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    • Havrilesky LJ, Scott AL, Davidson BA, Secord AA, Yang JC, Johnson FR, Gonzalez JM, Reed SD.
    • Gynecol Oncol. 2021 May 27:S0090-8258(21)00428-5. doi: 10.1016/j.ygyno.2021.05.022. Epub ahead of print.
    • Breast Cancer Predisposition Genes and Synthetic Lethality.
    • Neiger HE, Siegler EL, Shi Y.
    • Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.
    • Precision medicine for hereditary tumors in gynecologic malignancies.
    • Sekine M, Enomoto T.
    • J Obstet Gynaecol Res. 2021 May 25. doi: 10.1111/jog.14861. Epub ahead of print.
    • Review
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Homologous recombination deficiency: cancer predispositions and treatment implications.
    • Toh MR, Ngeow J.
    • Oncologist. 2021 May 22. doi: 10.1002/onco.13829. Epub ahead of print.
    • Metronomic oral cyclophosphamide in relapsed ovarian cancer.
    • Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R.
    • Int J Gynecol Cancer. 2021 May 20:ijgc-2021-002467. doi: 10.1136/ijgc-2021-002467. Epub ahead of print.
    • Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian).
    • Evrard C, Alexandre J.
    • Cancers (Basel). 2021 May 18;13(10):2434. doi: 10.3390/cancers13102434.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.
    • Paracchini L, D'Incalci M, Marchini S.
    • Cancers (Basel). 2021 May 14;13(10):2386. doi: 10.3390/cancers13102386.
    • MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer.
    • Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I.
    • Genes (Basel). 2021 May 14;12(5):742. doi: 10.3390/genes12050742.
    • Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    • Cecere SC, Musacchio L, Bartoletti M, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Naglieri E, Scollo P, Marchetti C, Raspagliesi F, Greggi S, Cinieri S, Bergamini A, Orditura M, Valabrega G, Scambia G, Martinelli F, De Matteis E, Cardalesi C, Loizzi V, Perniola G, Carella C, Scandurra G, Giannone G, Pignata S.
    • Int J Gynecol Cancer. 2021 May 14:ijgc-2020-002343. doi: 10.1136/ijgc-2020-002343. Epub ahead of print.
    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Marjolijn Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
    • Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER.
    • Gynecol Oncol Rep. 2021 May 5;36:100772. doi: 10.1016/j.gore.2021.100772.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
    • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA.
    • Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
    • An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.
    • Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu Y, Wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu W, Zhang X, Meng Y, Zhang B, Wang Y, Wang Q, Wu L.
    • Clin Cancer Res. 2021 May 1;27(9):2452-2458. doi: 10.1158/1078-0432.CCR-20-3546. Epub 2021 Feb 8.
    • Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    • Zhang R, Wang T, Lin J.
    • Anticancer Res. 2021 May;41(5):2277-2286. doi: 10.21873/anticanres.15003.
    • Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    • Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS.
    • Cancer Med. 2021 May;10(9):3045-3058. doi: 10.1002/cam4.3831. Epub 2021 Apr 3.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
    • Della Corte L, Foreste V, Di Filippo C, Giampaolino P, Bifulco G.
    • Expert Opin Investig Drugs. 2021 May;30(5):543-554. doi: 10.1080/13543784.2021.1901882. Epub 2021 Mar 24.
    • Review
    • Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    • Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN.
    • Gynecol Oncol. 2021 May;161(2):512-515. doi: 10.1016/j.ygyno.2021.01.037. Epub 2021 Feb 17.
    • Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    • Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B.
    • Gynecol Oncol. 2021 May;161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. Epub 2021 Mar 3.
    • Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series.
    • Kasherman L, Garg S, Tchrakian N, Clarke B, Karakasis K, Kim RH, Stockley TL, Dhani N, Oza AM, Lheureux S.
    • Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.
    • Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
    • Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P.
    • Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13.
    • Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    • Kaneko M.
    • Ann Pharmacother. 2021 Apr 29:10600280211013489. doi: 10.1177/10600280211013489. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients.
    • Stodtmann S, Nuthalapati S, Eckert D, Kasichayanula S, Joshi R, Bach BA, Mensing S, Menon R, Xiong H.
    • J Clin Pharmacol. 2021 Apr 24. doi: 10.1002/jcph.1875. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    • Giannone G, Scotto G, Katsaros D, De Giorgi U, Farolfi A, Borella F, Cosma S, Ferrero A, Mangiacotti S, Villa M, Tuninetti V, Ghisoni E, Turinetto M, Mittica G, Gemmiti S, Zavallone L, Aglietta M, Pasini B, Di Maio M, Valabrega G.
    • Gynecol Oncol. 2021 Apr 22:S0090-8258(21)00328-0. doi: 10.1016/j.ygyno.2021.04.018. Epub ahead of print.
    • Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
    • Cho A, Park JY, Lee SW, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT.
    • Arch Gynecol Obstet. 2021 Apr 19. doi: 10.1007/s00404-021-06013-x. Epub ahead of print.
    • FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.
    • Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson III DM, Hickson I, Tatum NJ, Rakha EA, Madhusudan S.
    • Cancers (Basel). 2021 Apr 14;13(8):E1866. doi: 10.3390/cancers13081866.
    • In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
    • Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES.
    • Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5.
    • Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
    • Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L.
    • Cancer Manag Res. 2021 Apr 8;13:3081-3100. doi: 10.2147/CMAR.S292992.
    • Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    • Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T.
    • Cancers (Basel). 2021 Apr 7;13(8):E1769. doi: 10.3390/cancers13081769.
    • Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    • Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK.
    • Gynecol Oncol. 2021 Apr 7:S0090-8258(21)00272-9. doi: 10.1016/j.ygyno.2021.04.002. Epub ahead of print.
    • The dystonia gene THAP1 controls DNA double-strand break repair choice.
    • Shinoda K, Zong D, Callen E, Wu W, Dumitrache LC, Belinky F, Chari R, Wong N, Ishikawa M, Stanlie A, Multhaupt-Buell T, Sharma N, Ozelius L, Ehrlich M, McKinnon PJ, Nussenzweig A.
    • Mol Cell. 2021 Apr 6:S1097-2765(21)00229-X. doi: 10.1016/j.molcel.2021.03.034. Epub ahead of print.
    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
    • Agarwal A, Baghmar S, Dodagoudar C, Qureshi S, Khurana A, Vaibhav V, Kumar G.
    • JCO Glob Oncol. 2021 Apr;7:506-511. doi: 10.1200/GO.20.00269.
    • Molecular disruption of DNA polymerase ß for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    • Ali R, Alblihy A, Miligy IM, Alabdullah ML, Alsaleem M, Toss MS, Algethami M, Abdel-Fatah T, Moseley P, Chan S, Mongan NP, Narayan S, Rakha EA, Madhusudan S.
    • Oncogene. 2021 Apr;40(14):2496-2508. doi: 10.1038/s41388-021-01710-y. Epub 2021 Mar 5.
    • Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
    • Patel PS, Algouneh A, Hakem R.
    • Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.
    • Review
    • Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).
    • Gadducci A, Aletti GD, Landoni F, Lazzari R, Mangili G, Olivas P, Pignata S, Salutari V, Sartori E, Scambia G, Zannoni GF, Sabbatini R, Lorusso D.
    • Tumori. 2021 Apr;107(2):100-109. doi: 10.1177/0300891620966382. Epub 2020 Oct 26.
    • Guideline. Review
    • Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?
    • Kozlowski M, Nowak K, Cymbaluk-Ploska A.
    • Int J Environ Res Public Health. 2021 Mar 26;18(7):3430. doi: 10.3390/ijerph18073430.
    • Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    • Naqvi MF, Vo HH, Vining D, Tsimberidou AM.
    • Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538.
    • The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
    • Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M, Barbieri E, Grandi G, Tagliafico E, Cortesi L.
    • Diagnostics (Basel). 2021 Mar 21;11(3):565. doi: 10.3390/diagnostics11030565.
    • Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    • Stok C, Kok YP, van den Tempel N, van Vugt MATM.
    • Nucleic Acids Res. 2021 Mar 21:gkab151. doi: 10.1093/nar/gkab151. Epub ahead of print.
    • Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    • Ewing A, Meynert A, Churchman M, Grimes G, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson MJ, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, Genomes Partnership TS, McMahon L, Matakidou A, Dougherty BA, March R, Barrett JC, McNeish IA, Biankin AV, Roxburgh P, Gourley C, Semple CA.
    • Clin Cancer Res. 2021 Mar 19:clincanres.CCR-20-4068-A.2020. doi: 10.1158/1078-0432.CCR-20-4068. Epub ahead of print.
    • Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
    • Akaev I, Rahimi S, Onifade O, Gardner FJE, Castells-Rufas D, Jones E, Acharige S, Yeoh CC.
    • Diagnostics (Basel). 2021 Mar 19;11(3):547. doi: 10.3390/diagnostics11030547.
    • Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    • Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ.
    • Gynecol Oncol. 2021 Mar 19:S0090-8258(21)00235-3. doi: 10.1016/j.ygyno.2021.03.015. Epub ahead of print.
    • NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund.
    • [No author given]
    • Precision Oncology News. Business & Policy. 2021 Mar 19.
    • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
    • Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators.
    • Lancet Oncol. 2021 Mar 18:S1470-2045(21)00073-5. doi: 10.1016/S1470-2045(21)00073-5. Epub ahead of print.
    • Serum Selenium Level Predicts 10-Year Survival after Breast Cancer.
    • Szwiec M, Marciniak W, Derkacz R, Huzarski T, Gronwald J, Cybulski C, Debniak T, Jakubowska A, Lener M, Falco M, Kladny J, Baszuk P, Duszynski J, Kotsopoulos J, Narod SA, Lubinski J.
    • Nutrients. 2021 Mar 16;13(3):953. doi: 10.3390/nu13030953.
    • Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
    • Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G, Lorusso D.
    • Cancers (Basel). 2021 Mar 15;13(6):1298. doi: 10.3390/cancers13061298.
    • PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
    • Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, He S.
    • Aging (Albany NY). 2021 Mar 11;13(6):8975-8988. doi: 10.18632/aging.202724. Epub 2021 Mar 11.
    • Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
    • Li Y, Zhang X, Gao Y, Shang C, Yu B, Wang T, Su J, Huang C, Wu Y, Guo H, Ha C.
    • Front Oncol. 2021 Mar 5;10:625866. doi: 10.3389/fonc.2020.625866.
    • The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    • Baert T, Ferrero A, Sehouli J, O Donnell DM, González-Martín A, Joly F, van der Velden J, Blecharz P, Tan DSP, Querleu D, Colombo N, du Bois A, Ledermann JA.
    • Ann Oncol. 2021 Mar 3:S0923-7534(21)00155-1. doi: 10.1016/j.annonc.2021.02.015. Epub ahead of print.
    • Review
    • Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
    • Conte C, Fagotti A, Avesani G, Trombadori C, Federico A, D'Indinosante M, Giudice MT, Pelligra S, Lodoli C, Marchetti C, Ferrandina G, Scambia G, Gallotta V.
    • Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690.
    • LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    • Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.
    • Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.
    • Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.
    • Park SJ, Kim HS.
    • Gland Surg. 2021 Mar;10(3):1268-1270. doi: 10.21037/gs.2020.04.08.
    • Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    • Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.
    • Gynecol Oncol. 2021 Mar;160(3):786-792. doi: 10.1016/j.ygyno.2020.12.007. Epub 2020 Dec 26.
    • Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    • Liang MI, Chen L, Hershman DL, Hillyer GC, Huh WK, Guyton A, Wright JD.
    • Gynecol Oncol. 2021 Mar;160(3):793-799. doi: 10.1016/j.ygyno.2020.12.015. Epub 2020 Dec 27.
    • Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.
    • Brennan A, Brennan D, Rees M, Hickey M.
    • Int J Gynecol Cancer. 2021 Mar;31(3):352-359. doi: 10.1136/ijgc-2020-002032. Epub 2020 Oct 30.
    • Review
    • Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
    • Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T.
    • J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10.
    • Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
    • Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF.
    • J Gynecol Oncol. 2021 Mar;32(2):e18. doi: 10.3802/jgo.2021.32.e18. Epub 2020 Dec 3.
    • Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
    • Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N.
    • J Gynecol Oncol. 2021 Mar;32(2):e21. doi: 10.3802/jgo.2021.32.e21. Epub 2021 Jan 6.
    • The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
    • Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H.
    • J Gynecol Oncol. 2021 Mar;32(2):e49. doi: 10.3802/jgo.2021.32.e49.
    • Nouvelles AMMs : niraparib et olaparib en première ligne dans les cancers de l’ovaire [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
    • Delaye M, Rodrigues M.
    • Bull Cancer. 2021 Feb 25:S0007-4551(21)00038-2. French. doi: 10.1016/j.bulcan.2021.01.003. Epub ahead of print.
    • Letter, [Article in French]
    • Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    • How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS.
    • Cancers (Basel). 2021 Feb 24;13(5):E946. doi: 10.3390/cancers13050946.
    • A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
    • Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA.
    • Sci Rep. 2021 Feb 24;11(1):4433. doi: 10.1038/s41598-021-82671-w.
    • BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
    • Salwa A, Ferraresi A, Chinthakindi M, Vallino L, Vidoni C, Dhanasekaran DN, Isidoro C.
    • Biomedicines. 2021 Feb 18;9(2):207. doi: 10.3390/biomedicines9020207.
    • Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.
    • Cheng LJ, Wong G, Chay WY, Ngeow J, Tan Y, Soon SS, Aziz MIA, Pearce F, Ng K.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Feb 16. doi: 10.1080/14737167.2021.1890587. Epub ahead of print.
    • Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
    • Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM.
    • Clin Cancer Res. 2021 Feb 15;27(4):983-991. doi: 10.1158/1078-0432.CCR-20-3089. Epub 2020 Nov 30.
    • How to start niraparib in real-world Asian ovarian cancer patients?
    • Hong SH.
    • J Gynecol Oncol. 2021 Feb 8:e36. doi: 10.3802/jgo.2021.32.e36. Epub ahead of print.
    • A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
    • Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Józwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC.
    • Int J Cancer. 2021 Feb 4. doi: 10.1002/ijc.33498. Epub ahead of print.
    • Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin.
    • Gorodnova TV, Sokolenko AP, Kotiv KB, Sokolova TN, Ivantsov AO, Guseynov KD, Nekrasova EA, Smirnova OA, Berlev IV, Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Feb 3;19(1):14. doi: 10.1186/s13053-021-00173-2.
    • Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    • Hinchcliff E, Chelariu-Raicu A, Westin SN.
    • Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):19-25. doi: 10.1097/GCO.0000000000000678.
    • Review
    • When in the treatment continuum to use PARP inhibition in ovarian cancer.
    • Mirza MR.
    • Clin Adv Hematol Oncol. 2021 Feb;19(2):84-86.
    • BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography.
    • Sobecki JN, Dryer KA, Mahajan AM, Spencer RJ.
    • Gynecol Oncol Rep. 2020 Dec 25;35:100690. doi: 10.1016/j.gore.2020.100690. eCollection 2021 Feb.
    • PARPi after PARPi in epithelial ovarian cancer.
    • Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, Ding K, Konecny G, Moore KN.
    • Gynecol Oncol Rep. 2021 Jan 11;35:100699. doi: 10.1016/j.gore.2021.100699. eCollection 2021 Feb.
    • DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
    • Pillay N, Brady R, Dey M, Morgan RD, Taylor SS.
    • Prog Biophys Mol Biol. 2021 Jan 29:S0079-6107(21)00005-5. doi: 10.1016/j.pbiomolbio.2021.01.004. Epub ahead of print.
    • Review
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
    • Molnár S, Vida B, Beke L, Méhes G, Póka R.
    • Diagnostics (Basel). 2021 Jan 19;11(1):E144. doi: 10.3390/diagnostics11010144.
    • Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
    • Tan DS, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC.
    • J Gynecol Oncol. 2021 Jan 18:e27. doi: 10.3802/jgo.2021.32.e27. Epub ahead of print.
    • Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    • Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G.
    • Drug Resist Updat. 2021 Jan 16:100744. doi: 10.1016/j.drup.2021.100744. Epub ahead of print.
    • Review
    • Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
    • Mansouri A, McGregor N, Dunn R, Dobbie S, Holmes J, Collins L, Nicum S.
    • BMJ Open. 2021 Jan 15;11(1):e041463. doi: 10.1136/bmjopen-2020-041463.
    • Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    • Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, Wu LY, Liu ZL, Gao YN, Wang DB, Lou G, Yang HY, Zhou Q, Kong BH, Huang Y, Chen LP, Li GL, An RF, Wang K, Zhang Y, Yan XJ, Lu X, Lu WG, Hao M, Wang L, Cui H, Chen QH, Abulizi G, Huang XH, Tian XF, Wen H, Zhang C, Hou JM, Mirza MR.
    • Ann Oncol. 2021 Jan 13:S0923-7534(21)00008-9. doi: 10.1016/j.annonc.2020.12.018. Epub ahead of print.
    • A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.
    • Zhang Y, Shi X, Zhang J, Chen X, Zhang P, Liu A, Zhu T.
    • Sci Rep. 2021 Jan 11;11(1):387. doi: 10.1038/s41598-020-79694-0.
    • Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study.
    • Plotti F, Terranova C, Guzzo F, De Cicco Nardone C, Luvero D, Bartolone M, Dionisi C, Benvenuto D, Fabris S, Ciccozzi M, Di Donato V, Panici PB, Angioli R.
    • Biomedicines. 2021 Jan 8;9(1):E55. doi: 10.3390/biomedicines9010055.
    • The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
    • Goldsberry WN, Summerlin SS, Guyton A, Caddell B, Huh WK, Kim KH, Liang MI.
    • Gynecol Oncol. 2021 Jan 4:S0090-8258(20)34254-2. doi: 10.1016/j.ygyno.2020.12.039. Epub ahead of print.
    • Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
    • Todisco E, Gigli F, Mantiero M, Sammassimo S, Pastano R, Ronchini C, Parma G, Lapresa MT, Iori AP, Bertolini F, Corsini C, Gregato G, Poletti C, Colombo N, Tarella C.
    • Int J Cancer. 2021 Jan 1;148(1):170-177. doi: 10.1002/ijc.33269. Epub 2020 Sep 16.
    • Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
    • Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J.
    • J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406.
    • Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
    • Kurnit KC, Fleming GF, Lengyel E.
    • Obstet Gynecol. 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173.
    • Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
    • Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L, Mu S, Zhang W, Li M.
    • Cancer Med. 2021 Jan;10(1):109-118. doi: 10.1002/cam4.3575. Epub 2020 Oct 31.
    • BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery.
    • Ponzone R.
    • Crit Rev Oncol Hematol. 2021 Jan;157:103128. doi: 10.1016/j.critrevonc.2020.103128. Epub 2020 Oct 19.
    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    • Michels J, Genestie C, Dunant A, Caron O, Lanoy E, Colomba E, Pommeret F, Rey A, Gouy S, Duvillard P, Teuff GL, Larue C, Savoye AM, Lhommé C, Leary A, Morice P, Pautier P.
    • Gynecol Oncol. 2021 Jan;160(1):77-82. doi: 10.1016/j.ygyno.2020.09.050. Epub 2020 Oct 12.
    • Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    • Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, Gao Y, Kong B, Lu X, Zhou Q, Wang Y, Chen Y, Lu W, Li W, Cheng Y, Liu J, Ma X, Zhang J.
    • Gynecol Oncol. 2021 Jan;160(1):175-181. doi: 10.1016/j.ygyno.2020.10.005. Epub 2020 Nov 27.
    • The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    • Haunschild CE, Tewari KS.
    • Gynecol Oncol. 2021 Jan;160(1):333-345. doi: 10.1016/j.ygyno.2020.09.043. Epub 2020 Oct 11.
    • Review
    • ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
    • Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S.
    • Int J Gynecol Cancer. 2021 Jan;31(1):134-138. doi: 10.1136/ijgc-2020-002073. Epub 2020 Oct 23.
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).
    • Rose PG, Yao M, Chambers LM, Mei L, Le P.
    • Gynecol Obstet (Sunnyvale). 2021;11(9):570. Epub 2021 Oct 7.
    • To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
    • Rose PG, Chambers LM, Kuznicki M.
    • Gynecol Obstet (Sunnyvale). 2021;11(7):561. Epub 2021 Aug 3.
    • Adverse events of PARP inhibitors.
    • Romanová M, Klát J.
    • Ceska Gynekol. 2021 Winter;86(1):54-60. English. doi: 10.48095/cccg202154.
    • Review. [Article in Czech, English]
    • Comparative efficacy and safety of PARP inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis.
    • Xu Y, Ding L, Tian Y, Bi M, Han N, Wang L.
    • Front Oncol. 2020 Dec 31;10:573801. doi: 10.3389/fonc.2020.573801.
    • PARP inhibitors in ovarian cancer: an overview of the practice-changing trials.
    • Foo T, George A, Banerjee S.
    • Genes Chromosomes Cancer. 2020 Dec 31. doi: 10.1002/gcc.22935. Epub ahead of print.
    • Review
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    • Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.
    • J Natl Cancer Inst. 2020 Dec 29:djaa193. doi: 10.1093/jnci/djaa193. Epub ahead of print.
    • Japanese Regulators Approve Lynparza for Ovarian, Prostate, Pancreatic Cancers.
    • [No author given]
    • Precision Oncology News. 2020 Dec 28.
    • The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.
    • Du ZH, Xia Y, Yang Q, Gao S.
    • Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. [First Published December 24, 2020.]
    • MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/ß-catenin in serous ovarian cancers.
    • Sun Y, Wu J, Dong X, Zhang J, Meng C, Liu G.
    • Transl Oncol. 2020 Dec 21;14(2):100987. doi: 10.1016/j.tranon.2020.100987. Epub ahead of print.
    • BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    • Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9708. doi: 10.3390/ijms21249708.
    • PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    • Gralewska P, Gajek A, Marczak A, Mikula M, Ostrowski J, Sliwinska A, Rogalska A.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9715. doi: 10.3390/ijms21249715.
    • PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
    • Riad A, Gitto SB, Lee H, Winters HD, Martorano PM, Hsieh CJ, Xu K, Omran DK, Powell DJ Jr, Mach RH, Makvandi M.
    • Molecules. 2020 Dec 19;25(24):E6029. doi: 10.3390/molecules25246029.
    • Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review.
    • Tao M, Cheng J, Wu X.
    • Onco Targets Ther. 2020 Dec 18;13:12979-12986. doi: 10.2147/OTT.S281302.
    • Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    • Cho HY, Kim YB, Park WH, No JH.
    • Cancer Res Treat. 2020 Dec 16. doi: 10.4143/crt.2020.1013. Epub ahead of print.
    • A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    • Gonzalez Martin A, Sanchez Lorenzo L, Colombo N, dePont Christensen R, Heitz F, Meirovitz M, Selle F, van Gorp T, Alvarez N, Sanchez J, Marqués C.
    • Int J Gynecol Cancer. 2020 Dec 14:ijgc-3-001633. doi: 10.1136/ijgc-2020-001633. Epub ahead of print.
    • Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.
    • Openshaw MR, McVeigh TP.
    • Front Digit Health. 2020 Dec 11;2:573010. doi: 10.3389/fdgth.2020.573010.
    • Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases.
    • Harada Y, Kubo M, Kai M, Yamada M, Zaguirre K, Ohgami T, Yahata H, Ohishi Y, Yamamoto H, Oda Y, Nakamura M.
    • Surg Case Rep. 2020 Dec 9;6(1):317. doi: 10.1186/s40792-020-01090-7.
    • A European, observational, prospective trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive ovarian cancer.
    • Pignata S, Scambia G, Villanucci A, Naglieri E, Ibarbia MA, Brusa F, Bourgeois H, Sorio R, Casado A, Reichert D, Dopchie C, De Rivas B, de Sande LM.
    • Oncologist. 2020 Dec 8. doi: 10.1002/onco.13630. Epub ahead of print.
    • Editorial: Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment.
    • Grabenstetter A, Lazaro C, Turashvili G.
    • Front Oncol. 2020 Dec 2;10:618369. doi: 10.3389/fonc.2020.618369.
    • Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    • Penn CA, Wong MS, Walsh CS.
    • JAMA Netw Open. 2020 Dec 1;3(12):e2028620. doi: 10.1001/jamanetworkopen.2020.28620.
    • Current practices on genetic testing in ovarian cancer.
    • Fostira F, Papadimitriou M, Papadimitriou C.
    • Ann Transl Med. 2020 Dec;8(24):1703. doi: 10.21037/atm-20-1422.
    • Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    • Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N.
    • Ann Transl Med. 2020 Dec;8(24):1706. doi: 10.21037/atm.2020.03.156.
    • Treatment of Recurrent Epithelial Ovarian Cancer.
    • Claussen C, Rody A, Hanker L.
    • Geburtshilfe Frauenheilkd. 2020 Dec;80(12):1195-1204. doi: 10.1055/a-1128-0280. Epub 2020 Dec 3.
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Dec;159(3):850-859. doi: 10.1016/j.ygyno.2020.09.018. Epub 2020 Sep 23.
    • Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    • Ciccone MA, Adams CL, Bowen C, Thakur T, Ricker C, Culver JO, Maoz A, Melas M, Idos GE, Jeyasekharan AD, Matsuo K, Roman LD, Gruber SB, McDonnell KJ.
    • Gynecol Oncol. 2020 Dec;159(3):869-876. doi: 10.1016/j.ygyno.2020.09.040. Epub 2020 Oct 5.
    • Homologous recombination deficiency real-time clinical assays, ready or not?
    • Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.
    • Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.
    • Review
    • Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    • Liu YL, Zhou QC, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner G, Broach V, O'Cearbhaill R, Konner JA, Grisham R, Aghajanian CA, Abu-Rustum NR, Tew W, Long Roche K.
    • Int J Gynecol Cancer. 2020 Dec;30(12):1915-1921. doi: 10.1136/ijgc-2020-001641. Epub 2020 Oct 26.
    • Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    • Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z.
    • J Enzyme Inhib Med Chem. 2020 Dec;35(1):1606-1615. doi: 10.1080/14756366.2020.1804382.
    • Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    • Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL.
    • Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
    • Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
    • Wei Y, Ou T, Lu Y, Wu G, Long Y, Pan X, Yao D.
    • PeerJ. 2020 Nov 24;8:e10414. doi: 10.7717/peerj.10414.
    • Clinically Relevant Response to Treatment with Olaparib in a Patient with Refractory Multidrug-Resistant Ovarian Cancer and Central Nervous System Involvement: A Case Report.
    • Morales Vázquez F, López Basave HN, Méndez Herrera MDC, Peña González RR.
    • Am J Case Rep. 2020 Nov 23;21:e925990. doi: 10.12659/AJCR.925990.
    • Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.
    • Singh B, Yang S, Krishna A, Sridhar S.
    • Front Chem. 2020 Nov 23;8:594619. doi: 10.3389/fchem.2020.594619.
    • Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.
    • Estati FL, Pirolli R, de Alencar VTL, Ribeiro ARG, Formiga MN, Torrezan GT, Carraro DM, Guimarães APG, Baiocchi G, da Costa AABA.
    • Ann Surg Oncol. 2020 Nov 21. doi: 10.1245/s10434-020-09366-w. Epub ahead of print.
    • Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
    • Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J.
    • Cancers (Basel). 2020 Nov 21;12(11):E3468. doi: 10.3390/cancers12113468.
    • Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
    • Hao J, Liu Y, Zhang T, He J, Zhao H, An R, Xue Y.
    • Crit Rev Oncol Hematol. 2020 Nov 19;157:103145. doi: 10.1016/j.critrevonc.2020.103145. Epub ahead of print.
    • Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    • Sheta R, Bachvarova M, Plante M, Renaud MC, Sebastianelli A, Gregoire J, Navarro JM, Perez RB, Masson JY, Bachvarov D.
    • J Transl Med. 2020 Nov 19;18(1):439. doi: 10.1186/s12967-020-02613-4.
    • Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China.
    • [No author given]
    • Precision Oncology News. 2020 Nov 16.
    • Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    • Poort H, Fenton ATHR, Thompson E, Dinardo MM, Liu JF, Arch JJ, Wright AA.
    • Gynecol Oncol. 2020 Nov 12:S0090-8258(20)34056-7. doi: 10.1016/j.ygyno.2020.10.034. Epub ahead of print.
    • European Commission Green Lights Lynparza for Prostate, Ovarian Cancer Indications.
    • [No author given]
    • Precision Oncology News. 2020 Nov 5.
    • First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
    • Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, Ray-Coquard I.
    • ESMO Open. 2020 Nov;5(6):e001110. doi: 10.1136/esmoopen-2020-001110.
    • Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    • Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA.
    • Gynecol Oncol. 2020 Nov;159(2):442-448. doi: 10.1016/j.ygyno.2020.09.006. Epub 2020 Sep 25.

    Identifier: NCT01847274: A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer. (ClinicalTrials.gov)

    • Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    • Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, Moss HA.
    • Gynecol Oncol. 2020 Nov;159(2):483-490. doi: 10.1016/j.ygyno.2020.08.003. Epub 2020 Aug 27.
    • Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    • Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K.
    • Gynecol Oncol. 2020 Nov;159(2):491-497. doi: 10.1016/j.ygyno.2020.08.013. Epub 2020 Sep 18.
    • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    • Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U.
    • Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x.
    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.
    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review
    • Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
    • Stemmer A, Shafran I, Stemmer SM, Tsoref D.
    • Cancers (Basel). 2020 Oct 18;12(10):E3026. doi: 10.3390/cancers12103026.
    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review
    • Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.
    • Care M, McCuaig J, Clarke B, Grenier S, Kim RH, Rouzbahman M, Stickle N, Bernardini M, Stockley TL.
    • Mol Oncol. 2020 Oct 8. doi: 10.1002/1878-0261.12817. Epub ahead of print.
    • FDA Approval Summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.
    • Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, Bloomquist E, Tang S, Gong Y, Sridhara R, Turcu FR, Chatterjee D, Saritas-Yildirim B, Ghosh S, Philip R, Pathak A, Gao JJ, Amiri-Kordestani L, Pazdur R, Beaver JA.
    • Oncologist. 2020 Oct 5. doi: 10.1002/onco.13551. Epub ahead of print.
    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review
    • Clinical assays for assessment of homologous recombination DNA repair deficiency.
    • Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33922-6. doi: 10.1016/j.ygyno.2020.09.029. Epub ahead of print.
    • Review
    • Advances in epithelial ovarian cancer.
    • Neesham D, Richards A, McGauran M.
    • Aust J Gen Pract. 2020 Oct;49(10):665-669.
    • Trabectedin for the therapy of ovarian cancer.
    • Evangelisti G, Barra F, D'Alessandro G, Tantari M, Stigliani S, Della Corte L, Bifulco G, Ferrero S.
    • Drugs Today (Barc). 2020 Oct;56(10):669-688. doi: 10.1358/dot.2020.56.10.3187001.
    • Review
    • The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    • Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL.
    • Gynecol Oncol. 2020 Oct;159(1):101-111. doi: 10.1016/j.ygyno.2020.05.045. Epub 2020 Aug 26.
    • PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
    • Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G.
    • Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.
    • The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
    • van Wijk LM, Vermeulen S, Meijers M, van Diest MF, ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MP.
    • Cancers (Basel). 2020 Sep 29;12(10):E2805. doi: 10.3390/cancers12102805.
    • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR.
    • Ann Oncol. 2020 Sep 28:S0923-7534(20)42164-7. doi: 10.1016/j.annonc.2020.08.2102. Epub ahead of print.
    • Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    • Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E.
    • Eur J Cancer. 2020 Sep 22;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub ahead of print.
    • Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    • Eakin CM, Norton TJ, Monk BJ, Chase DM.
    • Gynecol Oncol. 2020 Sep 21:S0090-8258(20)33817-8. doi: 10.1016/j.ygyno.2020.08.016. Epub ahead of print.
    • Review
    • EMA Committee Recommends Approval of Lynparza, Avastin in Platinum-Sensitive Ovarian Cancer.
    • [No author given]
    • Precision Oncology News. 2020 Sep 21.
    • A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
    • Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q.
    • J Ovarian Res. 2020 Sep 19;13(1):112. doi: 10.1186/s13048-020-00712-w.
    • Lynparza Maintenance Treatment in BRCA-Mutated Ovarian Cancer Shows Long-Term Benefit.
    • [No author given]
    • Precision Oncology News. 2020 Sep 18.
    • Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials.
    • Liposits G, Wulff CN, Otland A, Fokdal LU.
    • Ecancermedicalscience. 2020 Sep 15;14:1104. doi: 10.3332/ecancer.2020.1104.
    • The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    • Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL.
    • Int J Gynecol Cancer. 2020 Sep 14:ijgc-2020-001789. doi: 10.1136/ijgc-2020-001789. Epub ahead of print.
    • Review
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.
    • BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    • Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
    • EBioMedicine. 2020 Sep 11;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub ahead of print.
    • Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
    • Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Sep 6:ijgc-2020-001556. doi: 10.1136/ijgc-2020-001556. Epub ahead of print.
    • Review
    • DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    • McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM.
    • Int J Gynecol Cancer. 2020 Sep 2:ijgc-2020-001694. doi: 10.1136/ijgc-2020-001694. Epub ahead of print.
    • Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research.
    • Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L.
    • J Clin Med. 2020 Sep 1;9(9):E2830. doi: 10.3390/jcm9092830.
    • PARP inhibition as frontline therapy in ovarian cancer.
    • Moore KN, Pothuri B, Monk B, Coleman RL.
    • Clin Adv Hematol Oncol. 2020 Sep;18(9):550-556.
    • Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    • Gourley C, Miller RE, Hollis RL, Ledermann JA.
    • Curr Opin Oncol. 2020 Sep;32(5):442-450. doi: 10.1097/CCO.0000000000000660.
    • Review
    • Recent advancements in PARP inhibitors-based targeted cancer therapy.
    • Zhou P, Wang J, Mishail D, Wang CY.
    • Precis Clin Med. 2020 Sep;3(3):187-201. doi: 10.1093/pcmedi/pbaa030. Epub 2020 Aug 31.
    • Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
    • Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM.
    • Surg Oncol. 2020 Sep;34:40-45. doi: 10.1016/j.suronc.2020.03.001. Epub 2020 Mar 11.
    • Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    • Onstad M, Coleman RL, Westin SN.
    • Drugs. 2020 Aug 27. doi: 10.1007/s40265-020-01382-0. Epub ahead of print.
    • Review
    • Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.
    • Reverdy T, Sajous C, Péron J, Glehen O, Bakrin N, Gertych W, Lopez J, You B, Freyer G.
    • Cancers (Basel). 2020 Aug 25;12(9):2414. doi: 10.3390/cancers12092414.
    • Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2020 Aug 24. doi: 10.1007/s00404-020-05677-1. Epub ahead of print.
    • Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    • Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL.
    • J Clin Oncol. 2020 Aug 24:JCO1903107. doi: 10.1200/JCO.19.03107. Epub ahead of print.
    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.
    • Junshi Biosciences, Impact Therapeutics to Co-Develop PARP Inhibitor Senaparib in China.
    • [No author given]
    • Precision Oncology News. 2020 Aug 20.
    • Breast cancer (BRCA) gene testing in ovarian cancer.
    • Chelariu-Raicu A, Coleman RL.
    • Chin Clin Oncol. 2020 Aug 19:cco-20-4. doi: 10.21037/cco-20-4. Epub ahead of print.
    • LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS.
    • Le Page C, Amuzu S, Rahimi K, Gotlieb W, Ragoussis J, Tonin PN.
    • Semin Cancer Biol. 2020 Aug 19:S1044-579X(20)30177-2. doi: 10.1016/j.semcancer.2020.08.005. Epub ahead of print.
    • Review
    • Study: New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Aug 18.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • Moving Beyond BRCA - Incorporating Molecular Assays into Ovarian Cancer trials.
    • McMullen M, Karakasis K, Oza AM.
    • Clin Cancer Res. 2020 Aug 14. doi: 10.1158/1078-0432.CCR-20-2429. Epub ahead of print.
    • News
    • A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
    • Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB.
    • Pharmacoeconomics. 2020 Aug 14. doi: 10.1007/s40273-020-00949-9. Epub ahead of print.
    • PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    • Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC.
    • J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924. Epub ahead of print.
    • Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
    • Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M, Attademo L, Arenare L, Spina A, Russo D, Califano D, Losito NS, Setola SV, Franzese E, De Vita F, Orditura M, Pignata S.
    • Int J Gynecol Cancer. 2020 Aug 12:ijgc-2020-001540. doi: 10.1136/ijgc-2020-001540. Epub ahead of print.
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • Front-line ovarian cancer maintenance therapy: PARP inhibitors for all?
    • Berger J.
    • BJOG. 2020 Aug 8. doi: 10.1111/1471-0528.16450. Epub ahead of print.
    • Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    • Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33747-1. doi: 10.1016/j.ygyno.2020.07.097. Epub ahead of print.
    • Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer.
    • Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrère S, Quenet F, Gutowski M, Mourregot A, D'Hondt V, Coupier I, Vendrell J, Vilquin P, Pujol P, Solassol J, Mollevi C.
    • Cancers (Basel). 2020 Aug 5;12(8):E2184. doi: 10.3390/cancers12082184.
    • PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.
    • Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang L.
    • Front Oncol. 2020 Aug 4;10:1204. doi: 10.3389/fonc.2020.01204.
    • Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    • Barrington DA, Tubbs C, Smith HJ, Straughn JM Jr, Senter L, Cohn DE.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001550. doi: 10.1136/ijgc-2020-001550. Epub ahead of print.
    • BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.
    • Marchetti C, Minucci A, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001670. doi: 10.1136/ijgc-2020-001670. Epub ahead of print.

    Guidelines:

    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

    • Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    • DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN.
    • J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799. Epub ahead of print.
    • BRCA1 mutations in cancer: coordinating deficiencies in homologous recombination with tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Aug 3:canres.1830.2020. doi: 10.1158/0008-5472.CAN-20-1830. Epub ahead of print.
    • Review
    • Development of new medical treatment for epithelial ovarian cancer recurrence.
    • Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B, Vizza E.
    • Gland Surg. 2020 Aug;9(4):1149-1163. doi: 10.21037/gs-20-413.
    • PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
    • Lee EK, Matulonis UA.
    • Cancers (Basel). 2020 Jul 25;12(8):E2054. doi: 10.3390/cancers12082054.
    • Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance.
    • Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.
    • Cancer Discov. 2020 Jul 22:CD-19-1485. doi: 10.1158/2159-8290.CD-19-1485. Epub ahead of print.
    • Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    • Lorusso D, Marchetti C, Conte C, Giudice E, Bolomini G, Vertechy L, Ceni V, Ditto A, Ferrandina G, Raspagliesi F, Scambia G, Fagotti A.
    • Gynecol Oncol. 2020 Jul 20:S0090-8258(20)33657-X. doi: 10.1016/j.ygyno.2020.07.022. Epub ahead of print.
    • The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
    • Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, Foucher F, Levêque J, de la Motte Rouge T, Brousse S, Lavoué V.
    • J Clin Med. 2020 Jul 15;9(7):E2239. doi: 10.3390/jcm9072239.
    • PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: A meta-analysis.
    • Lin Q, Liu W, Xu S, Shang H, Li J, Guo Y, Tong J.
    • BJOG. 2020 Jul 12. doi: 10.1111/1471-0528.16411. Epub ahead of print.
    • Meta-Analysis
    • First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.
    • Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P.
    • Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874.
    • Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer.
    • [No author given]
    • FORCE. 2020 Jul 7.

    Original research:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    • The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
    • Yang Y, Du N, Xie L, Jiang J, Mo J, Hong J, Mao D, Ng DM, Shi H.
    • World J Surg Oncol. 2020 Jul 4;18(1):151. doi: 10.1186/s12957-020-01931-7.
    • Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
    • Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, Zhao M, Yang Q, Wang Y, Yang X.
    • Front Oncol. 2020 Jul 3;10:954. doi: 10.3389/fonc.2020.00954.
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • Sequence Now, Later, or Never?
    • Hagemann IS.
    • Clin Chem. 2020 Jul 1;66(7):883-885. doi: 10.1093/clinchem/hvaa053.
    • Case report

    Commentary:

    Commentary on Sequence Now, Later, or Never?

    • Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report.
    • Favier L, Truc G, Boidot R, Bengrine-Lefevre L.
    • Mol Clin Oncol. 2020 Jul;13(1):73-75. doi: 10.3892/mco.2020.2035. Epub 2020 Apr 27.
    • The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    • Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ.
    • Hum Reprod. 2020 Jun 30:deaa128. doi: 10.1093/humrep/deaa128. Epub ahead of print.
    • DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
    • Tomasova K, Cumova A, Seborova K, Horak J, Koucka K, Vodickova L, Vaclavikova R, Vodicka P.
    • Cancers (Basel). 2020 Jun 28;12(7):E1713. doi: 10.3390/cancers12071713.
    • Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer.
    • Gorodnova TV, Sokolenko AP, Kondratiev SV, Kotiv KB, Belyaev AM, Berlev IV, Imyanitov EN.
    • Invest New Drugs. 2020 Jun 26. doi: 10.1007/s10637-020-00965-8. Epub ahead of print.
    • Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service.
    • Patrizio A, Ludovica B, Giulia F, Claudio J, Nicoletta C, Francesco C.
    • Clin Ther. 2020 Jun 23:S0149-2918(20)30233-2. doi: 10.1016/j.clinthera.2020.04.015. Epub ahead of print.
    • Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    • Lee EK, Matulonis UA.
    • Expert Opin Emerg Drugs. 2020 Jun 22:1-23. doi: 10.1080/14728214.2020.1773791. Epub ahead of print.
    • Review
    • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
    • Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS.
    • J Clin Oncol. 2020 Jun 22:JCO1902404. doi: 10.1200/JCO.19.02404. Epub ahead of print.
    • Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study.
    • Majic A, Miše BP, Matkovic V, Lovasic IB, Katic K, Canjko I, Frobe A, Bajic Z, Vrdoljak E.
    • J Oncol. 2020 Jun 20;2020:6423936. doi: 10.1155/2020/6423936.
    • PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    • Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
    • Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
    • The forefront of ovarian cancer therapy: update on PARP inhibitors.
    • Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S.
    • Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. doi: 10.1016/j.annonc.2020.06.004. Epub ahead of print.
    • Review
    • Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
    • McMullen M, Karakasis K, Madariaga A, Oza AM.
    • Cancers (Basel). 2020 Jun 17;12(6):E1607. doi: 10.3390/cancers12061607.
    • Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
    • Huang XZ, Jia H, Xiao Q, Li RZ, Wang XS, Yin HY, Zhou X.
    • Front Oncol. 2020 Jun 16;10:958. doi: 10.3389/fonc.2020.00958.
    • BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.
    • Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M, Feit NZ, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ Jr, Friedman C, Cadoo K, Grisham R, Konner JA, O'Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, Zamarin D.
    • JCO Precis Oncol. 2020 Jun 16;4:PO.20.00069. doi: 10.1200/PO.20.00069.
    • Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
    • Evangelisti G, Barra F, Moioli M, Sala P, Stigliani S, Gustavino C, Costantini S, Ferrero S.
    • Expert Opin Investig Drugs. 2020 Jun 15. doi: 10.1080/13543784.2020.1783238. Epub ahead of print.
    • Review
    • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    • Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambi G, Fagotti A.
    • Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294-0. doi: 10.1016/j.ygyno.2020.06.479. Epub ahead of print
    • PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
    • Franzese E, Diana A, Centonze S, Pignata S, De Vita F, Ciardiello F, Orditura M.
    • Front Oncol. 2020 Jun 12;10:782. doi: 10.3389/fonc.2020.00782.
    • Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis.
    • Nahshon C, Barnett-Griness O, Segev Y, Schmidt M, Ostrovsky L, Lavie O.
    • Int J Gynecol Cancer. 2020 Jun 9:ijgc-2020-001392. doi: 10.1136/ijgc-2020-001392. Epub ahead of print.
    • Meta-analysis
    • PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 4.
    • Germline Testing In Advanced Cancer Can Lead to Targeted Tx.
    • Nelson R.
    • Medscape. Conference News. 2020 Jun 2.
    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
    • Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J.
    • Chin J Cancer Res. 2020 Jun;32(3):370-382. doi: 10.21147/j.issn.1000-9604.2020.03.08.
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Olaparib Makes OS Gains in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2020 May 29. doi: 10.1158/2159-8290.CD-NB2020-048. Epub ahead of print.
    • News
    • High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    • Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Mol Biol Rep. 2020 May 28. doi: 10.1007/s11033-020-05504-5. Epub ahead of print.
    • Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F.
    • Int J Mol Sci. 2020 May 27;21(11):E3805. doi: 10.3390/ijms21113805.
    • Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    • Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI.
    • Cancer Treat Rev. 2020 May 26;87:102040. doi: 10.1016/j.ctrv.2020.102040. Epub ahead of print.
    • Review
    • Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer - a potential management strategy in the era of COVID-19.
    • Vetter MH, Smrz SA, Copeland LJ, Cohn DE.
    • Am J Obstet Gynecol. 2020 May 23:S0002-9378(20)30569-X. doi: 10.1016/j.ajog.2020.05.037. Epub ahead of print.
    • EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    • Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM.
    • Clin Cancer Res. 2020 May 22:clincanres.4121.2019. doi: 10.1158/1078-0432.CCR-19-4121. Epub ahead of print.
    • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    • Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN.
    • Pharmacol Ther. 2020 May 22:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub ahead of print.
    • Review
    • Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
    • Milanesio MC, Giordano S, Valabrega G.
    • Cancers (Basel). 2020 May 21;12(5):E1315. doi: 10.3390/cancers12051315.
    • Wise Management of Ovarian Cancer: On the Cutting Edge.
    • Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • J Pers Med. 2020 May 21;10(2):E41. doi: 10.3390/jpm10020041.
    • New OS Data With Olaparib Support 'New Era' for Ovarian Cancer.
    • Davenport L.
    • Medscape. 2020 May 14.
    • Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
    • Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F.
    • EMBO Mol Med. 2020 May 13:e11217. doi: 10.15252/emmm.201911217. Epub ahead of print.
    • Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    • Lampert EJ, Zimmer AS, Padget MR, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri M, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM.
    • Clin Cancer Res. 2020 May 12:clincanres.0056.2020. doi: 10.1158/1078-0432.CCR-20-0056. Epub ahead of print.
    • Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.
    • Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B.
    • Cancers (Basel). 2020 May 11;12(5):E1206. doi: 10.3390/cancers12051206.
    • FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer.
    • [No author given]
    • GenomeWeb. 2020 May 11.
    • Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    • Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    • J Pathol Clin Res. 2020 May 11. doi: 10.1002/cjp2.168. Epub ahead of print.
    • The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
    • Jacob SL, Kiedrowski LA, Chae YK.
    • Heliyon. 2020 May 8;6(5):e03841. doi: 10.1016/j.heliyon.2020.e03841.
    • Integrating Genetic and Genomic Testing Into Oncology Practice.
    • Domchek SM, Mardis E, Carlisle JW, Owonikoko TK.
    • Am Soc Clin Oncol Educ Book. 2020 May;40:e259-e263. doi: 10.1200/EDBK_280607.
    • Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    • Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL.
    • Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9.

    Commentary, Introductory article:

    Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.

    • GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary
    • [No author given.]
    • GenomeWeb. Business & Policy. 2020 Apr 30.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • FDA approves niraparib for first-line maintenance of advanced ovarian cancer.
    • [No author given.]
    • U.S. Food & Drug Administration. Drug Approvals and Databases. 2020 Apr 29.

    Research review: Study: New FDA approval for maintenance therapy in ovarian cancer. (FORCE. XRAYS.)

    • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    • Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J.
    • Cancer Gene Ther. 2020 Apr 28. doi: 10.1038/s41417-020-0174-y. [Epub ahead of print]
    • Review
    • A single nucleotide variant of human PARP1 determines response to PARP inhibitors.
    • Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, Shoval I, Efroni S.
    • NPJ Precis Oncol. 2020 Apr 27;4:10. doi: 10.1038/s41698-020-0113-2. eCollection 2020.
    • Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
    • Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E.
    • Int J Gynecol Cancer. 2020 Apr 21. pii: ijgc-2019-000973. doi: 10.1136/ijgc-2019-000973. [Epub ahead of print]
    • Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    • Gralewska P, Gajek A, Marczak A, Rogalska A.
    • J Hematol Oncol. 2020 Apr 21;13(1):39. doi: 10.1186/s13045-020-00874-6.
    • Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
    • Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA.
    • Cancers (Basel). 2020 Apr 14;12(4). pii: E972. doi: 10.3390/cancers12040972.
    • Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
    • Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G.
    • J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19.
    • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
    • J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27.

    Commentary:

    BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.

    • Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
    • Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK.
    • Med Oncol. 2020 Apr 10;37(5):48. doi: 10.1007/s12032-020-01371-z.
    • Case report
    • Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    • Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S.
    • Int J Gynecol Cancer. 2020 Apr 9. pii: ijgc-2020-001288. doi: 10.1136/ijgc-2020-001288. [Epub ahead of print]
    • CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
    • Li J, Zhi X, Chen S, Shen X, Chen C, Yuan L, Guo J, Meng D, Chen M, Yao L.
    • Am J Cancer Res. 2020 Apr 1;10(4):1140-1155. eCollection 2020.
    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751. doi: 10.1007/s00280-020-04030-2. Epub 2020 Feb 13.
    • Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    • Choi MC, Hwang S, Kim S, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim TH, Kang H, An HJ.
    • Cancer Res Treat. 2020 Apr;52(2):634-644. doi: 10.4143/crt.2019.207. Epub 2020 Jan 6.
    • Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
    • Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.
    • Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.
    • Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    • Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S.
    • Biosci Rep. 2020 Mar 27;40(3). pii: BSR20192226. doi: 10.1042/BSR20192226.
    • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    • Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
    • Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
    • Ovarian Cancer Patients in Netherlands To Get 'Tumor-First' BRCA Testing.
    • Anderson A.
    • Precision Oncology News. 2020 Mar 23.
    • News
    • Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.
    • Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X.
    • J Ovarian Res. 2020 Mar 17;13(1):29. doi: 10.1186/s13048-020-00629-4.
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    • Kerliu L, Myruski S, Bhatti A, Soni P, Petrosius P, Pervanas HC, Horton ER.
    • Ann Pharmacother. 2020 Mar 16:1060028020912749. doi: 10.1177/1060028020912749. [Epub ahead of print]
    • Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
    • Ibrahim EM, Refae AA, Bayer AM, Sagr ER.
    • Future Oncol. 2020 Mar 13. doi: 10.2217/fon-2020-0057. [Epub ahead of print]
    • Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    • Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS.
    • Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176-1. doi: 10.1016/j.ygyno.2020.02.030. [Epub ahead of print]
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    • Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    • BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
    • Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    • Liontos M, Sotiropoulou M, Kaparelou M, Tzannis K, Tsironis G, Kyriazoglou A, Tsiara A, Zakopoulou R, Koutsoukos K, Zagouri F, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Bamias A.
    • Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224-9. doi: 10.1016/j.ygyno.2020.03.008. [Epub ahead of print]
    • The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
    • Patel M, Nowsheen S, Maraboyina S, Xia F.
    • Cell Biosci. 2020 Mar 11;10:35. doi: 10.1186/s13578-020-00390-7. eCollection 2020.
    • Prognostic value of radiological recurrence patterns in ovarian cancer.
    • Roze JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, Scholten RJPM, Zweemer RP.
    • Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219-5. doi: 10.1016/j.ygyno.2020.03.003. [Epub ahead of print]
    • Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer.
    • You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M, Liang Z.
    • Front Oncol. 2020 Mar 10;10:295. doi: 10.3389/fonc.2020.00295. eCollection 2020.
    • RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
    • Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.
    • Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.
    • Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    • Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • BMC Cancer. 2020 Mar 4;20(1):185. doi: 10.1186/s12885-020-6688-8.
    • Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
    • Chevalier LM, Billaud A, Fronteau S, Dauvé J, Patsouris A, Verriele V, Morel A.
    • Mol Diagn Ther. 2020 Mar 2. doi: 10.1007/s40291-020-00452-z. [Epub ahead of print]
    • PARP and PARG inhibitors in cancer treatment.
    • Slade D.
    • Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119. Epub 2020 Feb 6.
    • PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
    • Konstantinopoulos PA, Lheureux S, Moore KN.
    • Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-16. doi: 10.1200/EDBK_288015.
    • Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
    • Gu L, Du N, Jin Q, Li S, Xie L, Mo J, Shen Z, Mao D, Ji J, Khadaroo PA, Chen B.
    • Crit Rev Oncol Hematol. 2020 Mar;147:102888. doi: 10.1016/j.critrevonc.2020.102888. Epub 2020 Jan 30.
    • Review
    • A profile on the FoundationFocus CDxBRCA tests.
    • Ford L, Wolford JE, Brown SM, Randall LM.
    • Expert Rev Mol Diagn. 2020 Mar;20(3):285-292. doi: 10.1080/14737159.2020.1701438. Epub 2020 Feb 6.
    • Review
    • Therapeutic options for mucinous ovarian carcinoma.
    • Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.
    • Gynecol Oncol. 2020 Mar;156(3):552-560. doi: 10.1016/j.ygyno.2019.12.015. Epub 2020 Jan 2.
    • SGO Special Topic: PARP Inhibitor Maintenance Therapy after Initial Chemotherapy.
    • Armstrong DK, Eskander R, Cearbhaill R, Pothuri B.
    • Gynecologic Oncology. Podcasts. 2020 Mar.
    • Podcast
    • [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
    • Marom I, Lavie O, Ostrovsky L, Kugelman N, Schmidt M, Segev Y.
    • Harefuah. 2020 Mar;159(3):175-180.
    • Review, [Article in Hebrew]
    • Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
    • Randall M, Burgess K, Buckingham L, Usha L.
    • J Natl Compr Canc Netw. 2020 Mar;18(3):223-228. doi: 10.6004/jnccn.2019.7378.
    • Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
    • Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH.
    • Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702.
    • Review

    Editorial:

    Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy.

    Press: Cancer Threat Persists After Risk-Reducing Surgery — Occult tumors, recurrence, new cancers after prophylactic salpingo-oophorectomy. (Medpage Today)

    • Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
    • Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno JC, Cardenas-Goicoechea J.
    • Obstet Gynecol Sci. 2020 Mar;63(2):205-208. doi: 10.5468/ogs.2020.63.2.205. Epub 2020 Feb 5.
    • The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
    • Curtin NJ.
    • Cancers (Basel). 2020 Feb 29;12(3). pii: E564. doi: 10.3390/cancers12030564.
    • Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.
    • Aust S, Schwameis R, Gagic T, Müllauer L, Langthaler E, Prager G, Grech C, Reinthaller A, Krainer M, Pils D, Grimm C, Polterauer S.
    • Cancers (Basel). 2020 Feb 27;12(3). pii: E548. doi: 10.3390/cancers12030548.
    • Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
    • Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P.
    • Pleura Peritoneum. 2020 Feb 26;5(1):20190029. doi: 10.1515/pp-2019-0029.
    • Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
    • Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J.
    • Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.
    • Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
    • Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM.
    • Diagnostics (Basel). 2020 Feb 22;10(2). pii: E121. doi: 10.3390/diagnostics10020121.
    • PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    • Lightfoot M, Montemorano L, Bixel K.
    • Curr Oncol Rep. 2020 Feb 17;22(3):29. doi: 10.1007/s11912-020-0873-4.
    • Review
    • Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    • Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N.
    • Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.
    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Feb 13. doi: 10.1007/s00280-020-04030-2. [Epub ahead of print]
    • Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination.
    • [No author given]
    • GenomeWeb. 2020 Feb 11.
    • Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
    • Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V.
    • Support Care Cancer. 2020 Feb 11. doi: 10.1007/s00520-020-05320-4. [Epub ahead of print]
    • Guidelines
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis.
    • Ricci AD, Rizzo A, Novelli M, Tavolari S, Palloni A, Tober N, Abbati F, Mollica V, DE Lorenzo S, Turchetti D, DI Marco M, Brandi G.
    • Anticancer Res. 2020 Feb;40(2):597-608. doi: 10.21873/anticanres.13989.
    • Review
    • PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
    • Segan L, Beekman A, Parfrey S, Perrin M.
    • Eur Heart J Case Rep. 2019 Dec 31;4(1):1-5. doi: 10.1093/ehjcr/ytz230. eCollection 2020 Feb.
    • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.
    • J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.

    Letter:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • PARP inhibitors: a tsunami of indications in different malignancies.
    • Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR.
    • Pharmacogenomics. 2020 Feb;21(3):221-230. doi: 10.2217/pgs-2019-0113.
    • Review
    • Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
    • Lieberman HB.
    • Transl Cancer Res. 2020 Feb;9(2):418-420. doi: 10.21037/tcr.2019.12.102.

    Original research:

    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

    • Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.
    • Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K.
    • Curr Drug Targets. 2020 Jan 28. doi: 10.2174/1389450121666200128161733. [Epub ahead of print]
    • Review
    • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
    • J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960. [Epub ahead of print]
    • Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug.
    • [No author given]
    • GenomeWeb. 2020 Jan 23.
    • Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    • Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, Alvarez Secord A, Yang JC, Johnson FR, Gonzalez JM, Reed SD.
    • Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070-6. doi: 10.1016/j.ygyno.2020.01.026. [Epub ahead of print]
    • A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer: Emerging Treatment Options in Advanced Ovarian Cancer.
    • Alvarez RD, Liu J.
    • National Comprehensive Cancer Network. Continuing Education. 2020 Jan 21.
    • CME Webinar
    • BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Teixeira LA, Candido Dos Reis FJ.
    • Target Oncol. 2020 Jan 20. doi: 10.1007/s11523-020-00697-y. [Epub ahead of print]
    • Review
    • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    • Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA.
    • Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060-3. doi: 10.1016/j.ygyno.2020.01.018. [Epub ahead of print]
    • Genetic testing for epithelial ovarian cancer.
    • Amin N, Chaabouni N, George A.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Jan 16. pii: S1521-6934(20)30017-1. doi: 10.1016/j.bpobgyn.2020.01.005. [Epub ahead of print]
    • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    • Bixel K, Vetter M, Davidson B, Berchuck A, Cohn D, Copeland L, Fowler JM, Havrilesky L, Lee PS, O'Malley DM, Salani R, Valea F, Alvarez Secord A, Backes F.
    • Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837-2. doi: 10.1016/j.ygyno.2019.12.016. [Epub ahead of print]
    • Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    • Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H.
    • Biomed Pharmacother. 2020 Jan 10;123:109661. doi: 10.1016/j.biopha.2019.109661. [Epub ahead of print]
    • A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    • Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL.
    • Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873-6. doi: 10.1016/j.ygyno.2019.12.043. [Epub ahead of print]
    • MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
    • Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S.
    • J Exp Clin Cancer Res. 2020 Jan 2;39(1):3. doi: 10.1186/s13046-019-1490-7.
    • Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date.
    • Montemorano L, Lightfoot MD, Bixel K.
    • Onco Targets Ther. 2019 Dec 27;12:11497-11506. doi: 10.2147/OTT.S195552. eCollection 2019.
    • Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients.
    • Gallardo-Rincón D, Álvarez-Gómez RM, Montes-Servín E, Toledo-Leyva A, Montes-Servín E, Michel-Tello D, Alamilla-García G, Bahena-González A, Hernández-Nava E, Fragoso-Ontiveros V, Espinosa-Romero R, Cetina-Pérez L.
    • Transl Oncol. 2019 Dec 20;13(2):212-220. doi: 10.1016/j.tranon.2019.11.003. [Epub ahead of print]
    • Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
    • Rusan M, Andersen RF, Jakobsen A, Steffensen KD.
    • Eur J Cancer. 2019 Dec 19;125:121-129. doi: 10.1016/j.ejca.2019.11.012. [Epub ahead of print]
    • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.
    • N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.

    Research news, Commentary:

    Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

    Research news: Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer. (FORCE. XRAYS.)

    Press, Conference report: PARP Inhibitors Move Into First-Line for Ovarian Cancer. (Medscape Oncology)

    See PubMed abstract for multiple additional related items.

    • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
    • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.
    • N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.

    Research news, Commentary:

    Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

    Press, Conference report: PARP Inhibitors Move Into First-Line for Ovarian Cancer. (Medscape Oncology)

    • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    • Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators.
    • N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.

    Research news, Commentary:

    Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

    • Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
    • Longo DL.
    • N Engl J Med. 2019 Dec 19;381(25):2471-2474. doi: 10.1056/NEJMe1914488.
    • Research news, Commentary

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    Original research:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    • Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
    • Whitehair R, Peres LC, Mills AM.
    • Int J Gynecol Pathol. 2019 Dec 16. doi: 10.1097/PGP.0000000000000657. [Epub ahead of print]
    • Treatment of recurrent epithelial ovarian cancer.
    • Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L.
    • Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500.
    • BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
    • Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N.
    • Nat Commun. 2019 Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6.
    • Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
    • Trenner A, Sartori AA.
    • Front Oncol. 2019 Dec 10;9:1388. doi: 10.3389/fonc.2019.01388. eCollection 2019.
    • Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.
    • Sahin ID, Jönsson JM, Hedenfalk I.
    • Oncotarget. 2019 Dec 10;10(65):6981-6996. doi: 10.18632/oncotarget.27363. eCollection 2019 Dec 10.
    • Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    • Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.
    • Br J Cancer. 2019 Dec 9. doi: 10.1038/s41416-019-0674-4. [Epub ahead of print]
    • Mechanisms of PARP inhibitor resistance in ovarian cancer.
    • Kubalanza K, Konecny GE.
    • Curr Opin Obstet Gynecol. 2019 Dec 6. doi: 10.1097/GCO.0000000000000600. [Epub ahead of print]
    • Review
    • Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
    • Palacios J, de la Hoya M, Bellosillo B, de Juan I, Matías-Guiu X, Lázaro C, Palanca S, Osorio A, Rojo F, Rosa-Rosa JM, Cigudosa JC.
    • Virchows Arch. 2019 Dec 3. doi: 10.1007/s00428-019-02709-3. [Epub ahead of print]
    • Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
    • Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D.
    • Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319. doi: 10.1055/a-1039-4458. Epub 2019 Dec 11.
    • Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response.
    • Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita F, Caraglia M, Pignata S, Ciardiello F, Orditura M.
    • Front Oncol. 2019 Nov 29;9:1289. doi: 10.3389/fonc.2019.01289. eCollection 2019.
    • Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.
    • Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X.
    • J Ovarian Res. 2019 Nov 28;12(1):117. doi: 10.1186/s13048-019-0594-1.
    • Paraneoplastic opsoclonus-myoclonus syndrome as a presentation of high grade serous ovarian cancer.
    • Stewart KT, Lee JS, Stuart G.
    • Gynecol Oncol Rep. 2019 Nov 21;30:100511. doi: 10.1016/j.gore.2019.100511. eCollection 2019 Nov.
    • A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
    • Rettenmaier MA, Micha JP, Bohart R, Goldstein BH.
    • Eur J Obstet Gynecol Reprod Biol. 2019 Nov 9;244:101-105. doi: 10.1016/j.ejogrb.2019.10.047. [Epub ahead of print]
    • A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    • Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, Scalone S, Sorio R, Dreussi E, Zanusso C, De Mattia E, Roncato R, Cecchin E, Giorda G, De Vita S, Dal Bo M, Puglisi F, Toffoli G.
    • Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603-8. doi: 10.1016/j.ygyno.2019.10.019. [Epub ahead of print]
    • Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study.
    • Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG.
    • J Clin Med. 2019 Nov 8;8(11). pii: E1920. doi: 10.3390/jcm8111920.
    • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    • Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C.
    • Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569-0. doi: 10.1016/j.ygyno.2019.10.012. [Epub ahead of print]
    • Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    • Farolfi A, Lorusso D, Pignata S, De Giorgi U.
    • J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055. [Epub ahead of print]

    Original research:

    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

    • Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    • Sokolenko AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, Ivantsov AO, Iyevleva AG, Savonevich EL, Kotiv KB, Kuligina ES, Imyanitov EN.
    • Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776. [Epub ahead of print]
    • Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer.
    • [No author given.]
    • FORCE. XRAY. 2019 Nov 5.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    • Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S.
    • Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607-5. doi: 10.1016/j.ygyno.2019.10.023. [Epub ahead of print]
    • Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
    • Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2019 Nov 4;12(1):103. doi: 10.1186/s13048-019-0579-0.
    • Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.
    • Mariniello A, Ghisoni E, Righi L, Catino A, Chiari R, Del Conte A, Barbieri F, Cecere F, Gelibter A, Giajlevra M, Parra HS, Zichi C, DI Maio M, Valabrega G, Novello S.
    • In Vivo. 2019 Nov-Dec;33(6):2021-2026. doi: 10.21873/invivo.11699.
    • Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    • Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.
    • Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8.

    Commentary:

    Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

    • Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
    • Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.
    • Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.
    • Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    • Xu L, Wu Y, Che X, Zhao J, Wang F, Wang P, Qu X, Liu Y, Li Z.
    • DNA Cell Biol. 2019 Oct 29. doi: 10.1089/dna.2019.4826. [Epub ahead of print]
    • FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers.
    • Ray T.
    • GenomeWeb. 2019 Oct 29.
    • Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
    • Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G.
    • Arch Clin Cases. 2021 [2019?] Oct 27;6(3):69-75. doi: 10.22551/2019.24.0603.10156.
    • Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
    • Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, Bernard L, Peccatori F, Colombo N, Viale G, Barberis M, Guerini-Rocco E.
    • Cancers (Basel). 2019 Oct 24;11(11). pii: E1641. doi: 10.3390/cancers11111641.
    • Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    • Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N.
    • Invest New Drugs. 2019 Oct 24. doi: 10.1007/s10637-019-00867-4. [Epub ahead of print]
    • Review
    • FDA Approves GSK's Zejula Alongside Myriad Genetics CDx for Advanced Ovarian Cancer.
    • [No author given]
    • GenomeWeb. 2019 Oct 23.
    • A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    • Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A.
    • Am J Surg Pathol. 2019 Oct 22. doi: 10.1097/PAS.0000000000001391. [Epub ahead of print]
    • Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    • Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.
    • Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]
    • Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    • Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA.
    • Gynecol Oncol. 2019 Oct 17. pii: S0090-8258(19)31549-5. doi: 10.1016/j.ygyno.2019.09.021. [Epub ahead of print]
    • Review
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
    • Page CL, Chung J, Rahimi K, Kobel M, Provencher D, Masson AMM.
    • Curr Drug Targets. 2019 Oct 16. doi: 10.2174/1389450120666191016143836. [Epub ahead of print]
    • Review
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    • Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB.
    • Cancer Treat Rev. 2019 Oct 9;80:101909. doi: 10.1016/j.ctrv.2019.101909. [Epub ahead of print]
    • Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    • Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545-8. doi: 10.1016/j.ygyno.2019.09.020. [Epub ahead of print]
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Success for First-Line PARP Inhibition in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 7. doi: 10.1158/2159-8290.CD-NB2019-121. [Epub ahead of print]
    • News
    • PARP Inhibitors Center Stage for Ovarian Cancer — PRIMA, PAOLA-1, and VELIA Trials
    • Banerjee SN.
    • Medscape Oncology. 2019 Oct 7.
    • Who Should Consider Genetic Counseling and Testing for Breast and Ovarian Cancer? Guidelines Have Expanded.
    • [No author given]
    • My Gene Counsel. 2019 Oct 3.
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Genetic testing in ovarian cancer - clinical impact and current practices.
    • Knabben L, Imboden S, Mueller MD.
    • Horm Mol Biol Clin Investig. 2019 Oct 2. pii: /j/hmbci.ahead-of-print/hmbci-2019-0025/hmbci-2019-0025.xml. doi: 10.1515/hmbci-2019-0025. [Epub ahead of print]
    • Review
    • Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
    • Cybulska P, Hayes SA, Spirtos A, Rafizadeh MJ, Filippova OT, Leitao M, Zivanovic O, Sonoda Y, Mueller J, Lakhman Y, Long K, Chi DS.
    • Int J Gynecol Cancer. 2019 Oct 1. pii: ijgc-2019-000829. doi: 10.1136/ijgc-2019-000829. [Epub ahead of print]
    • Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
    • Cao Y, Chen H, Huang Y, Hu H.
    • Cancer Rep (Hoboken). 2019 Oct;2(5):e1180. doi: 10.1002/cnr2.1180. Epub 2019 May 9.
    • Niraparib - A promising drug with hematological toxicity.
    • Patibandla NS, Monga DK.
    • J Oncol Pharm Pract. 2019 Oct;25(7):1749-1753. doi: 10.1177/1078155218800156. Epub 2018 Oct 6.
    • Case report
    • Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
    • Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • Yonsei Med J. 2019 Oct;60(10):914-923. doi: 10.3349/ymj.2019.60.10.914.
    • PARP Inhibitors Move Into First-Line for Ovarian Cancer.
    • Chustecka Z.
    • Medscape Oncology. 2019 Sep 29.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers.
    • Ismael M, Webb R, Ajaz M, Kirkby KJ, Coley HM.
    • Cancers (Basel). 2019 Sep 25;11(10). pii: E1429. doi: 10.3390/cancers11101429.
    • Advances in the treatment of ovarian cancer using PARP inhibitors and the underlying mechanism of resistance.
    • Wang L, Wang Q, Xu Y, Han L.
    • Curr Drug Targets. 2019 Sep 25. doi: 10.2174/1389450120666190925123507. [Epub ahead of print]
    • Review
    • Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    • Poveda AM, Davidson R, Blakeley C, Milner A.
    • Future Oncol. 2019 Sep 25. doi: 10.2217/fon-2019-0343. [Epub ahead of print]
    • PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.
    • Murthy P, Muggia F.
    • Cancer Drug Resist. 2019 Sep 19;2(3):665-679. doi: 10.20517/cdr.2019.002.
    • Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    • Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Sep 19. pii: ijgc-2019-000757. doi: 10.1136/ijgc-2019-000757. [Epub ahead of print]
    • ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
    • Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.
    • Mol Cancer Ther. 2019 Sep 18. pii: molcanther.0242.2019. doi: 10.1158/1535-7163.MCT-19-0242. [Epub ahead of print]
    • Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    • Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR.
    • J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917. [Epub ahead of print]
    • Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
    • Yu Y, Durairaj C, Shi H, Wang DD.
    • J Clin Pharmacol. 2019 Sep 6. doi: 10.1002/jcph.1520. [Epub ahead of print]
    • Olaparib in the treatment of ovarian cancer.
    • Washington CR, Richardson DL, Moore KN.
    • Future Oncol. 2019 Sep 3. doi: 10.2217/fon-2019-0271. [Epub ahead of print]
    • Review
    • Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    • Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X.
    • Int J Cancer. 2019 Sep 1;145(5):1209-1220. doi: 10.1002/ijc.32143. Epub 2019 Feb 23.
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Sep;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Epub 2019 Dec 12.
    • Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
    • Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ.
    • Biochem Pharmacol. 2019 Sep;167:125-132. doi: 10.1016/j.bcp.2018.10.011. Epub 2018 Oct 17.
    • Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
    • Gray S, Khor XY, Yiannakis D.
    • BMJ Case Rep. 2019 Aug 28;12(8). pii: e230738. doi: 10.1136/bcr-2019-230738.
    • Case report
    • Hopes and failures in front-line ovarian cancer therapy.
    • Tsibulak I, Zeimet AG, Marth C.
    • Crit Rev Oncol Hematol. 2019 Aug 14;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. [Epub ahead of print]
    • The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib.
    • Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0419.2019. doi: 10.1158/1078-0432.CCR-19-0419. [Epub ahead of print]
    • The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    • Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0448.2019. doi: 10.1158/1078-0432.CCR-19-0448. [Epub ahead of print]
    • Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.
    • Jorge S, Swisher EM, Norquist BM, Pennington KP, Gray HJ, Urban RR, Garcia RL, Doll KM.
    • Gynecol Oncol Rep. 2019 Aug 9;29:113-117. doi: 10.1016/j.gore.2019.08.001. eCollection 2019 Aug.
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    • Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, Brøsen K, Bjørge L, Mäenpää J.
    • Cancer Chemother Pharmacol. 2019 Aug 2. doi: 10.1007/s00280-019-03917-z. [Epub ahead of print]
    • Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    • Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • Diagnostics (Basel). 2019 Aug 1;9(3). pii: E87. doi: 10.3390/diagnostics9030087.
    • Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
    • Lai CH, Vallikad E, Lin H, Yang LY, Jung SM, Liu HE, Ou YC, Chou HH, Lin CT, Huang HJ, Huang KG, Qiu J, Hung YC, Wu TI, Chang WY, Tan KT, Lin CY, Chao A, Chang CJ.
    • J Gynecol Oncol. 2019 Jul 26. doi: 10.3802/jgo.2020.31.e5. [Epub ahead of print]
    • Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy.
    • Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L.
    • Oncologist. 2019 Jul 25. pii: theoncologist.2019-0272. doi: 10.1634/theoncologist.2019-0272. [Epub ahead of print]
    • GSK Drug Helps Ovarian Cancer Patients Live Longer in Late-Stage Study.
    • Zainab Hussain N, Aripaka P.
    • Medscape Oncology. 2019 Jul 18.
    • Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
    • Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ1, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.
    • Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.
    • Conference report, Commentary
    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    • Vanacker H, Romeo C, Ray-Coquard I.
    • Curr Opin Oncol. 2019 Jul 10. doi: 10.1097/CCO.0000000000000557. [Epub ahead of print]
    • Review
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.
    • Ashour M, Ezzat Shafik H.
    • Cancer Manag Res. 2019 Jul 8;11:6275-6284. doi: 10.2147/CMAR.S206817. eCollection 2019.
    • FoundationOne CDx Approved as Companion Diagnostic to Lynparza in Ovarian Cancer.
    • [No author given.]
    • Clinical Omics. 2019 Jul 3.
    • The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
    • Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.
    • J BUON. 2019 Jul-Aug;24(4):1538-1543.
    • Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations.
    • Garcia A, Frahm C, Jeter JM, Abraham I, Chambers SK, Cragun JM, McBride A.
    • J Adv Pract Oncol. 2019 Jul;10(5):428-439. doi: 10.6004/jadpro.2019.10.5.2. Epub 2019 Jul 1.
    • The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.
    • Yim GW, Suh DH, Kim JW, Kim SC, Kim YT.
    • J Gynecol Oncol. 2019 Jul;30(4):e91. doi: 10.3802/jgo.2019.30.e91.
    • Fallopian Tube Carcinoma.
    • Stasenko M, Fillipova O, Tew WP.
    • J Oncol Pract. 2019 Jul;15(7):375-382. doi: 10.1200/JOP.18.00662. Epub 2019 Jul 8.

    Commentary:

    Rapidly Changing Landscape of Fallopian Tube Carcinoma.

    • Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2019 Jun 21.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Jun 20. pii: mdz192. doi: 10.1093/annonc/mdz192. [Epub ahead of print]
    • Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.
    • Kondrashova O, Ho GY, Au-Yeung G, Leas L, Boughtwood T, Alsop K, Zapparoli G, Dobrovic A, Ko YA, Hsu AL, Love CJ, Lunke S, Wakefield MJ, McNally O, Quinn M, Ananda S, Neesham D, Hamilton A, Grossi M, Freimund A, Kanjanapan Y, Rischin D, Traficante N, Bowtell D, Scott CL, Christie M, Taylor GR, Mileshkin L, Waring PM; Australian Ovarian Cancer Study Group.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 20];3:1-18. doi: 10.1200/PO.19.00019.
    • AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    • Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.
    • J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009. [Epub ahead of print]

    Letter, Commentary:

    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.

    • European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations.
    • [No author given]
    • Precision Oncology News (GenomeWeb). 2019 Jun 18.
    • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
    • Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    • Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.
    • Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.
    • Clinical Impact of RANK Signalling in Ovarian Cancer.
    • Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.
    • Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.
    • Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    • Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.
    • J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238. [Epub ahead of print]
    • High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    • Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.
    • Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079. [Epub ahead of print]

    Commentary:

    Clarifying the role of EMSY in DNA repair in ovarian cancer

    • PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    • Cook SA, Tinker AV.
    • BioDrugs. 2019 Jun;33(3):255-273. doi: 10.1007/s40259-019-00347-4.
    • Review
    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    • Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.
    • Gynecol Oncol. 2019 Jun;153(3):568-573. doi: 10.1016/j.ygyno.2019.03.004. Epub 2019 Mar 12.
    • Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
    • Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
    • Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
    • Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.
    • Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.
    • Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.
    • Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    • Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.
    • Crit Rev Oncol Hematol. 2019 May 25;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. [Epub ahead of print]
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 May 24. pii: e9982. doi: 10.15252/emmm.201809982. [Epub ahead of print]
    • Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    • Ledermann JA, Pujade-Lauraine E.
    • Ther Adv Med Oncol. 2019 May 22;11:1758835919849753. doi: 10.1177/1758835919849753. eCollection 2019.
    • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    • Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CR Collaborative Network (Supplementary 1), Singh N.
    • Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181-3. doi: 10.1016/j.ygyno.2019.04.679. [Epub ahead of print]
    • PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
    • Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N.
    • Diagnostics (Basel). 2019 May 18;9(2). pii: E55. doi: 10.3390/diagnostics9020055.
    • Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
    • Lheureux S, Braunstein M, Oza AM.
    • CA Cancer J Clin. 2019 May 17. doi: 10.3322/caac.21559. [Epub ahead of print]
    • [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
    • Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K.
    • Rev Med Suisse. 2019 May 15;15(651):1027-1031.
    • Review, [Article in French]
    • Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
    • Eskilera GG, Cecener G, Dikmen G, Egeli U, Tunca B.
    • Curr Drug Deliv. 2019 May 14. doi: 10.2174/1567201816666190515105532. [Epub ahead of print]
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
    • Jiang X, Li W, Li X, Bai H, Zhang Z.
    • Cancer Manag Res. 2019 May 10;11:4371-4390. doi: 10.2147/CMAR.S200524. eCollection 2019.
    • Biomarkers of drug resistance in ovarian cancer - an update.
    • Davidson B.
    • Expert Rev Mol Diagn. 2019 May 10. doi: 10.1080/14737159.2019.1618187. [Epub ahead of print]
    • Review
    • Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.
    • Baldwin P, Ohman AW, Medina JE, McCarthy ET, Dinulescu DM, Sridhar S.
    • Front Oncol. 2019 May 10;9:353. doi: 10.3389/fonc.2019.00353. eCollection 2019.
    • Veliparib: a new therapeutic option in ovarian cancer?
    • Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G.
    • Future Oncol. 2019 May 10. doi: 10.2217/fon-2018-0883. [Epub ahead of print]
    • Review
    • Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    • Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P.
    • Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504-9. doi: 10.1016/j.ygyno.2019.04.009. [Epub ahead of print]
    • Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
    • Pan K, Gong J, Huynh K, Cristea M.
    • Target Oncol. 2019 May 8. doi: 10.1007/s11523-019-00641-9. [Epub ahead of print]
    • Review
    • Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    • Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    • J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.
    • Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    • da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    • BMC Cancer. 2019 May 6;19(1):422. doi: 10.1186/s12885-019-5622-4.
    • Rucaparib and Niraparib in Advanced Ovarian Cancer.
    • Redelico T.
    • J Adv Pract Oncol. 2019 May-Jun;10(4):402-408. doi: 10.6004/jadpro.2019.10.4.8. Epub 2019 Mar 1.
    • Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
    • Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacokinet. 2019 May;58(5):615-625. doi: 10.1007/s40262-018-0714-x.
    • Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    • Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, Swisher EM.
    • Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.

    Editorial:

    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

    • ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    • Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    • Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 20.
    • Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    • Naumann RW, Coleman RL, Brown J, Moore KN.
    • Gynecol Oncol. 2019 May;153(2):436-444. doi: 10.1016/j.ygyno.2019.02.008. Epub 2019 Feb 12.
    • Review
    • BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    • Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.
    • Int J Gynecol Cancer. 2019 May;29(4):779-786. doi: 10.1136/ijgc-2018-000175. Epub 2019 Mar 5.
    • Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
    • Miller RE, Crusz SM, Ledermann JA.
    • Future Oncol. 2019 Apr 30. doi: 10.2217/fon-2019-0057. [Epub ahead of print]
    • Review
    • Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
    • Macedo GS, Alemar B, Ashton-Prolla P.
    • Genet Mol Biol. 2019 Apr 29. pii: S1415-47572019005015101. doi: 10.1590/1678-4685-GMB-2018-0104. [Epub ahead of print]
    • Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
    • Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.
    • Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.
    • Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.
    • Liu L, Liu P, Liang Z, Li R, Shen M, Xu H, Ren D, Ji M, Yang Y, Lu Z, Shang D, Zhang Y, Liu H, Tu Z.
    • Anticancer Drugs. 2019 Apr 16. doi: 10.1097/CAD.0000000000000793. [Epub ahead of print]
    • Review
    • Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials.
    • Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X.
    • Cancer Manag Res. 2019 Apr 16;11:3061-3078. doi: 10.2147/CMAR.S191107. eCollection 2019.
    • Detecting the mutational signature of homologous recombination deficiency in clinical samples.
    • Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
    • Nat Genet. 2019 Apr 15. doi: 10.1038/s41588-019-0390-2. [Epub ahead of print]
    • Rucaparib in the landscape of PARP inhibition in ovarian cancer.
    • Colomba E, Pautier P, Pommeret F, Leary A.
    • Expert Rev Anticancer Ther. 2019 Apr 12. doi: 10.1080/14737140.2019.1607302. [Epub ahead of print]
    • Review
    • N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance.
    • Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.
    • Cancer Res. 2019 Apr 9. pii: canres.3592.2018. doi: 10.1158/0008-5472.CAN-18-3592. [Epub ahead of print]
    • Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
    • Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O’Connor MJ, Clarke AR, Smalley MJ.
    • Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5.
    • Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    • Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA.
    • Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018.
    • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    • Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.
    • Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4. [Epub ahead of print]

    Commentary:

    Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

    • 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    • Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.
    • Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.
    • PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    • Jiang X, Li X, Li W, Bai H, Zhang Z.
    • J Cell Mol Med. 2019 Apr;23(4):2303-2313. doi: 10.1111/jcmm.14133. Epub 2019 Jan 22.
    • Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
    • Moore DC, Ringley JT, Patel J.
    • J Pharm Pract. 2019 Apr;32(2):219-224. doi: 10.1177/0897190017743131. Epub 2017 Nov 22.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    • Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ.
    • Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
    • Rucaparib: A Review in Ovarian Cancer.
    • Shirley M.
    • Target Oncol. 2019 Apr;14(2):237-246. doi: 10.1007/s11523-019-00629-5.
    • Review
    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition.
    • Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.
    • Mol Cancer Ther. 2019 Mar 29. pii: molcanther.0770.2018. doi: 10.1158/1535-7163.MCT-18-0770. [Epub ahead of print]
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
    • Madariaga A, Lheureux S, Oza AM.
    • Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416.
    • Epithelial ovarian cancer.
    • Lheureux S, Gourley C, Vergote I, Oza AM.
    • Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.
    • Review
    • DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    • Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.
    • Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
    • TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer.
    • Harrison P.
    • Medscape Oncology. Conference News. 2019 Mar 18.
    • Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
    • Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL.
    • Cancers (Basel). 2019 Mar 13;11(3). pii: E354. doi: 10.3390/cancers11030354.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    • Foote JR, Secord AA, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ.
    • Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.
    • Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    • Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA.
    • Gynecol Oncol. 2019 Mar;152(3):560-567. doi: 10.1016/j.ygyno.2018.12.009. Epub 2019 Jan 9.
    • PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    • Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.
    • J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
    • Review
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
    • Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L.
    • J Med Genet. 2019 Mar;56(3):195-198. doi: 10.1136/jmedgenet-2017-105140. Epub 2018 Mar 13.
    • Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
    • Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis AM, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Buettner R, Schweiger MR.
    • J Mol Diagn. 2019 Mar;21(2):198-213. doi: 10.1016/j.jmoldx.2018.10.007. Epub 2018 Dec 19.
    • Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.
    • Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M.
    • J Obstet Gynaecol Res. 2019 Mar;45(3):743-747. doi: 10.1111/jog.13851. Epub 2018 Nov 22.
    • Case report
    • Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
    • Guy H, Walder L, Fisher M.
    • Pharmacoeconomics. 2019 Mar;37(3):391-405. doi: 10.1007/s40273-018-0745-z.
  1. s
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    • Murthy P, Muggia F.
    • Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Exaggeration of PFS by blinded, independent, central review (BICR).
    • Stone A, Gebski V, Davidson R, Bloomfield R, Bartlett JW, Sabin A.
    • Ann Oncol. 2019 Feb 1;30(2):332-338. doi: 10.1093/annonc/mdy514.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Exaggeration of PFS by blinded, independent, central review (BICR).
    • Stone A, Gebski V, Davidson R, Bloomfield R, Bartlett JW, Sabin A.
    • Ann Oncol. 2019 Feb;30(2):332-338. doi: 10.1093/annonc/mdy514. Epub 2019 Dec 24.
    • A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    • Velázquez C, Esteban-Cardeñosa EM, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Durán M, Infante M.
    • Breast. 2019 Feb;43:91-96. doi: 10.1016/j.breast.2018.11.010. Epub 2018 Nov 29.
    • Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    • Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.
    • Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.
    • BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
    • Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.
    • Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.
    • Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    • Washington C, Gunderson CC, Moore KN.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.
    • Review
    • Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
    • McCann KE.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):12-17. doi: 10.1097/GCO.0000000000000517.
    • Review
    • [Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)].
    • Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.
    • Gynecol Obstet Fertil Senol. 2019 Feb;47(2):111-119. doi: 10.1016/j.gofs.2018.12.011. Epub 2019 Jan 28.
    • Review, [Article in French]
    • [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    • de la Motte Rouge T, Ray-Coquard I, You B.
    • Gynecol Obstet Fertil Senol. 2019 Feb;47(2):222-237. doi: 10.1016/j.gofs.2019.01.002. Epub 2019 Jan 29.
    • Review, [Article in French]
    • Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    • Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dientsmann R, Oaknin A.
    • Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12.
    • Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    • Mullen MM, Kuroki LM, Thaker PH.
    • Gynecol Oncol. 2019 Feb;152(2):416-425. doi: 10.1016/j.ygyno.2018.10.023. Epub 2018 Nov 5.
    • Review
    • Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    • Wu L, Zhong L.
    • J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.
    • PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
    • Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, Rueda BR.
    • Mol Cancer Res. 2019 Feb;17(2):431-445. doi: 10.1158/1541-7786.MCR-18-0594. Epub 2018 Nov 6.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
    • Rivkin SE, Moon J, Iriarte DS, Bailey E, Sloan HL, Goodman GE, BonDurant AE, Velijovich D, Wahl T, Jiang P, Shah CA, Drescher C, Fer MF, Kaplan HG, Ellis ED.
    • Int J Gynecol Cancer. 2019 Jan 29. pii: ijgc-2018-000035. doi: 10.1136/ijgc-2018-000035. [Epub ahead of print]
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    • Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH.
    • BMC Cancer. 2019 Jan 10;19(1):44. doi: 10.1186/s12885-018-5250-4.
    • GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
    • Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A.
    • Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
    • Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    • Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.
    • Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24.
    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
    • Matthews Hew T, Zuberi L.
    • J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619864989. doi: 10.1177/2324709619864989.
    • The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    • Yap TA, Plummer R, Azad NS, Helleday T.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):185-195. doi: 10.1200/EDBK_238473.
    • The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer.
    • Monk BJ, Randall LM, Grisham RN.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):e141-e151. doi: 10.1200/EDBK_239007.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    • Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H.
    • Gynecol Oncol. 2019 Jan;152(1):157-165. doi: 10.1016/j.ygyno.2018.10.027. Epub 2018 Nov 7.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    • Li N, Wang Y, Deng W, Lin SH.
    • Anticancer Agents Med Chem. 2019;19(2):206-212. doi: 10.2174/1871520618666181109164645.
    • Review
    • DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
    • López-Camarillo C, Rincón DG, Ruiz-García E, Astudillo-de la Vega H, Marchat LA.
    • Curr Protein Pept Sci. 2019;20(4):316-323. doi: 10.2174/1389203719666180914091537.
    • Review
    • Experiencia con el uso de olaparib en pacientes con cáncer de ovario.
    • Gallardo-Rincón D, Alamilla-García G, Montes-Servín E, Morales-Vázquez F, Cano-Blanco C, Coronel-Martínez J, Bahena-González A, Gerson-Cwilich R, Isla-Ortiz D, Toledo-Leyva A, Montes-Servín E, Michel-Tello D, Espinosa-Romero R.
    • Gac Med Mex. 2019;155(6):585-589. doi: 10.24875/GMM.19005494.
    • Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    • Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S.
    • Pol J Pathol. 2019;70(2):115-126. doi: 10.5114/pjp.2019.82905.
    • Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    • N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.

    Editorial:

    Progress in BRCA-Mutated Ovarian Cancer.

    • USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    • Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
    • Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
    • PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
    • Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ.
    • Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
    • Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    • Faraoni I, Graziani G.
    • Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487.
    • Principles of clinical management of ovarian cancer.
    • Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN.
    • Chin Clin Oncol. 2018 Dec;7(6):56. doi: 10.21037/cco.2018.10.06.
    • How safe is rucaparib in ovarian cancer?
    • Cosgrove CM, O'Malley DM.
    • Expert Opin Drug Saf. 2018 Dec;17(12):1249-1255. doi: 10.1080/14740338.2018.1550067. Epub 2018 Dec 11.
    • Review
    • Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
    • Dal Molin GZ, Westin SN, Coleman RL.
    • Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14.
    • Review
    • Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    • Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J.
    • Gynecol Oncol. 2018 Dec;151(3):477-480. doi: 10.1016/j.ygyno.2018.10.003. Epub 2018 Oct 8.
    • Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
    • Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl JC, Schmutzler RK, Hahnen E.
    • Hum Mutat. 2018 Dec;39(12):2040-2046. doi: 10.1002/humu.23653. Epub 2018 Oct 3.
    • Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
    • Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES.
    • J Cancer Res Clin Oncol. 2018 Dec;144(12):2449-2456. doi: 10.1007/s00432-018-2753-y. Epub 2018 Sep 25.
    • Maintenance olaparib in advanced ovarian cancer.
    • Burki TK.
    • Lancet Oncol. 2018 Dec;19(12):e671. doi: 10.1016/S1470-2045(18)30816-7. Epub 2018 Oct 25.
    • Research news
    • Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study.
    • Eriksson I, Wettermark B, Bergfeldt K.
    • Target Oncol. 2018 Dec;13(6):725-733. doi: 10.1007/s11523-018-0604-z.
    • Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
    • Heo YA, Dhillon S.
    • Target Oncol. 2018 Dec;13(6):801-808. doi: 10.1007/s11523-018-0606-x.
    • Review
    • Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
    • Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S.
    • Int J Nanomedicine. 2018 Nov 29;13:8063-8074. doi: 10.2147/IJN.S186881. eCollection 2018.
    • Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    • Kurnit KC, Coleman RL, Westin SN.
    • Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.
    • Review
    • Review of Immune Therapies Targeting Ovarian Cancer.
    • Fan CA, Reader J, Roque DM.
    • Curr Treat Options Oncol. 2018 Nov 14;19(12):74. doi: 10.1007/s11864-018-0584-3.
    • Review
    • Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
    • Pearre DC, Tewari KS.
    • Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018.
    • Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
    • Burgess BT, Kolesar JM.
    • Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18.
    • Review
    • Secondary cytoreduction in ovarian cancer: who really benefits?
    • Giudice MT, D'Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, Petrillo M.
    • Arch Gynecol Obstet. 2018 Nov;298(5):873-879. doi: 10.1007/s00404-018-4915-1. Epub 2018 Sep 25.
    • Review
    • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    • Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.
    • Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.
    • The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
    • Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.
    • Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3.
    • Mechanisms of PARP inhibitor sensitivity and resistance.
    • D'Andrea AD.
    • DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.
    • Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.
    • Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M.
    • Eur Radiol. 2018 Nov;28(11):4849-4859. doi: 10.1007/s00330-018-5389-z. Epub 2018 May 8.
    • A Case of Immune-Mediated Liver Injury Induced by Olaparib.
    • Tufoni M, Serena Ricci C, Zaccherini G.
    • Hepatology. 2018 Nov;68(5):2039-2041. doi: 10.1002/hep.30119. Epub 2018 Oct 13.
    • Case report
    • Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
    • Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J.
    • J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93.
    • Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.
    • Harold JA, Free SC, Bradley WH.
    • Gynecol Oncol Rep. 2018 Oct 28;26:91-93. doi: 10.1016/j.gore.2018.10.011. eCollection 2018 Nov.
    • Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.
    • Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.
    • Int J Mol Sci. 2018 Oct 19;19(10). pii: E3249. doi: 10.3390/ijms19103249.
    • Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    • Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.
    • Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.
    • Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    • Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J.
    • Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24.

    Press: 'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance. (Medscape Oncology)

    • Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    • Stewart J, George A, Banerjee S.
    • Expert Rev Anticancer Ther. 2018 Oct;18(10):947-958. doi: 10.1080/14737140.2018.1510323. Epub 2018 Aug 24.
    • Review
    • The role of niraparib for the treatment of ovarian cancer.
    • Ethier JL, Lheureux S, Oza AM.
    • Future Oncol. 2018 Oct;14(25):2565-2577. doi: 10.2217/fon-2018-0101. Epub 2018 Jun 1.
    • Review
    • Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
    • Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN.
    • Int J Gynecol Cancer. 2018 Oct;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352.
    • A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    • van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.
    • Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
    • Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL.
    • Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.
    • Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer.
    • Filipi JG, Penson RT.
    • NCCN Continuing Education. 2018 Sep 25.
    • A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    • Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.
    • Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
    • Shen JP, Ideker T.
    • J Mol Biol. 2018 Sep 14;430(18 Pt A):2900-2912. doi: 10.1016/j.jmb.2018.06.026. Epub 2018 Jun 20.
    • Role of PARP Inhibitors in BRCA-Related Malignancies.
    • Iqbal S, Rattu MA, Shah N.
    • US Pharm. 2018 Sep 14;9(43):HS10-HS16
    • PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    • Konstantinopoulos PA, Matulonis UA.
    • Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
    • Commentary, Review

    Review:

    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.

    • FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    • Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.
    • Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.
    • Review

    Commentary, Review:

    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.

    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Inherited gynaecological cancers.
    • George A.
    • Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465.
    • Review
    • Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    • Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    • Gynecol Oncol. 2018 Sep;150(3):534-544. doi: 10.1016/j.ygyno.2018.07.002. Epub 2018 Jul 17.
    • Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
    • McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice.
    • J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.
    • Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
    • Ringley JT, Moore DC, Patel J, Rose MS.
    • P T. 2018 Sep;43(9):549-556.
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    • Cardoso FC, Goncalves S, Mele PG, Liria NC, Sganga L, Diaz Perez I, Podesta EJ, Solano AR.
    • Hum Genomics. 2018 Aug 13;12(1):39. doi: 10.1186/s40246-018-0171-5.
    • The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
    • Guo XX, Wu HL, Shi HY, Su L, Zhang X.
    • Cancer Manag Res. 2018 Aug 10;10:2553-2562. doi: 10.2147/CMAR.S169558. eCollection 2018.
    • Safety and dose modification for patients receiving niraparib.
    • Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.
    • Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di LJ.
    • Clin Cancer Res. 2018 Aug 1;24(15):3560-3571. doi: 10.1158/1078-0432.CCR-17-3862. Epub 2018 Apr 16.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    • Ventriglia J, Paciolla I, Cecere SC, Pisano C, Di Napoli M, Arenare L, Setola SV, Losito NS, Califano D, Orditura M, Pignata S.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):498-503. doi: 10.1016/j.clon.2018.01.008. Epub 2018 Feb 9.
    • Review
    • Niraparib for the treatment of ovarian cancer.
    • Essel KG, Moore KN.
    • Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2.
    • Review
    • Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    • Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.
    • Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17.

    Research news:

    PARP inhibitors and quality of life in ovarian cancer.

    • Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
    • Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E.
    • Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17.

    Research news:

    PARP inhibitors and quality of life in ovarian cancer.

    • Niraparib: A Review in Ovarian Cancer.
    • Heo YA, Duggan ST.
    • Target Oncol. 2018 Aug;13(4):533-539. doi: 10.1007/s11523-018-0582-1.
    • Review
    • Using PARP Inhibitors in Advanced Ovarian Cancer.
    • O'Cearbhaill RE.
    • Oncology (Williston Park). 2018 Jul 15;32(7). pii: 614793.
    • BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    • Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    • Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
    • An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    • Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer HN, Lyons JF, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.
    • Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.
    • Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
    • Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.
    • Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.
    • Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.
    • Dal Molin GZ, Omatsu K, Sood AK, Coleman RL.
    • Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483. doi: 10.1177/1758835918778483. eCollection 2018.
    • Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series.
    • Matsuo K, Spragg SE, Ciccone MA, Blake EA, Ricker C, Pham HQ, Roman LD.
    • Gynecol Oncol Rep. 2018 Jun 20;25:98-101. doi: 10.1016/j.gore.2018.06.011. eCollection 2018 Aug.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di L
    • Clin Cancer Res. 2018 Jun 12. doi: 10.1158/1078-0432.CCR-17-3862. [Epub ahead of print]
    • Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    • Mirza MR, Pignata S, Ledermann JA.
    • Ann Oncol. 2018 Jun 1;29(6):1366-1376. doi: 10.1093/annonc/mdy174.
    • Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
    • Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.
    • Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.
    • Management of newly diagnosed or recurrent ovarian cancer.
    • Matulonis UA.
    • Clin Adv Hematol Oncol. 2018 Jun;16(6):426-437.
    • Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    • Moore KN, Birrer MJ.
    • Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28.
    • Review
    • Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    • Dai Y, Sun C, Feng Y, Jia Q, Zhu B.
    • J Cell Mol Med. 2018 May 31. doi: 10.1111/jcmm.13678. [Epub ahead of print]
    • Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    • Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.
    • Drug Des Devel Ther. 2018 May 29;12:1501-1509. doi: 10.2147/DDDT.S124447. eCollection 2018.
    • Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.
    • Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G.
    • Cureus. 2018 May 24;10(5):e2685. doi: 10.7759/cureus.2685.
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
    • Delgado-Ortega L, Ginés Rubió J, Garcías de España MDC, Carcedo D, Cordero Puentes L, Moya de Alarcón C.
    • Farm Hosp. 2018 May 1;42(3):95-102. doi: 10.7399/fh.10904.
    • Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    • Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P.
    • Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23.
    • Review
    • Rucaparib: a new treatment option for ovarian cancer.
    • Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Lorusso D.
    • Expert Opin Pharmacother. 2018 May;19(7):765-771. doi: 10.1080/14656566.2018.1464557. Epub 2018 Apr 19.
    • Review
    • New Therapies for Ovarian Cancer.
    • Armstrong DK.
    • J Natl Compr Canc Netw. 2018 May;16(5S):632-635. doi: 10.6004/jnccn.2018.0034.
    • Review
    • Olaparib in Breast Cancer: PFS Is Significant but OS Is Not.
    • Castellino AM.
    • Medscape. Medscape Medical News. 2018 Apr 18.
    • Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus.
    • Capoluongo E, Scambia G, Nabholtz JM.
    • Oncotarget. 2018 Apr 13;9(28):19463-19468. doi: 10.18632/oncotarget.24728. eCollection 2018 Apr 13.
    • Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
    • Dasa SSK, Diakova G, Suzuki R, Mills AM, Gutknecht MF, Klibanov AL, Slack-Davis JK, Kelly KA.
    • Theranostics. 2018 Apr 11;8(10):2782-2798. doi: 10.7150/thno.23050. eCollection 2018.
    • Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
    • Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.
    • Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.
    • PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    • Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC.
    • Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20.
    • Crosstalk of DNA double-strand break repair pathways in PARP inhibitor treatment of BRCA1/2-mutated Cancer.
    • Sunada S, Nakanishi A, Miki Y.
    • Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6.
    • [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
    • Shimodaira H.
    • Gan To Kagaku Ryoho. 2018 Apr;45(4):587-592.
    • Review, [Article in Japanese]
    • The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    • Moore KN, Mirza MR, Matulonis UA.
    • Gynecol Oncol. 2018 Apr;149(1):214-220. doi: 10.1016/j.ygyno.2018.01.011. Epub 2018 Feb 4.
    • Review
    • Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    • Fang L, Wang H, Li P.
    • Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
    • Targeting DNA repair: the genome as a potential biomarker.
    • Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA.
    • J Pathol. 2018 Apr;244(5):586-597. doi: 10.1002/path.5025. Epub 2018 Feb 10.
    • Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature.
    • Herold N, Wappenschmidt B, Markiefka B, Keupp K, Kröber S, Hahnen E, Schmutzler R, Rhiem K.
    • Oncol Lett. 2018 Apr;15(4):4093-4096. doi: 10.3892/ol.2018.7836. Epub 2018 Jan 22.
    • Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    • Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.
    • BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.
    • Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.
    • Colombo I, Lheureux S, Oza AM.
    • Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018.
    • Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
    • Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.
    • The NCI-MATCH trial and precision medicine in gynecologic cancers.
    • Barroilhet L, Matulonis U.
    • Gynecol Oncol. 2018 Mar;148(3):585-590. doi: 10.1016/j.ygyno.2018.01.008. Epub 2018 Feb 1.
    • Review
    • Major clinical research advances in gynecologic cancer in 2017.
    • Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2018 Mar;29(2):e31. doi: 10.3802/jgo.2018.29.e31.
    • Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
    • Jerzak KJ, Deghan Manshadi S, Ng P, Maganti M, McCuaig JM, Bulter M, Oza A, Mackay HJ.
    • J Oncol Pharm Pract. 2018 Mar;24(2):83-90. doi: 10.1177/1078155216679028. Epub 2016 Nov 17.
    • Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    • Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, Soper JT, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.
    • Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.
    • Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.
    • Ganesan S.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-4. doi: 10.1200/PO.18.00001.

    Case report:

    Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    Original research:

    Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

    • Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.
    • Mylavarapu S, Das A, Roy M.
    • Front Oncol. 2018 Feb 5;8:16. doi: 10.3389/fonc.2018.00016. eCollection 2018.
    • Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    • Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.
    • Mol Pharm. 2018 Feb 5;15(2):472-485. doi: 10.1021/acs.molpharmaceut.7b00843. Epub 2018 Jan 22.
    • Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    • Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W.
    • Cancer Chemother Pharmacol. 2018 Feb;81(2):255-267. doi: 10.1007/s00280-017-3483-6. Epub 2017 Nov 30.
    • Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    • McCann KE.
    • Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428.
    • Review
    • The development of PARP as a successful target for cancer therapy.
    • Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.
    • Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26.
    • Review
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.
    • Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM.
    • J Genet Couns. 2018 Feb;27(1):131-139. doi: 10.1007/s10897-017-0130-7. Epub 2017 Aug 5.
    • PARP Inhibitors for the Treatment of Ovarian Cancer.
    • Cortesi L, Toss A, Cucinotto I.
    • Curr Cancer Drug Targets. 2018;18(9):877-893. doi: 10.2174/1568009618666180308104646.
    • Review
    • PARP Inhibitors in Ovarian Cancer.
    • Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G.
    • Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256.
    • Review
    • Gene aberration profile of tumors of adolescent and young adult females.
    • Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.
    • Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.
    • Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    • Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP.
    • Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620-7. doi: 10.1016/j.ygyno.2017.12.029. [Epub ahead of print]
    • Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    • Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.
    • BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.
    • Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
    • Markman M.
    • Womens Health (Lond). 2018 Jan-Dec;14:1745505717750694. doi: 10.1177/1745505717750694.
    • Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    • Wan B, Dai L, Wang L, Zhang Y, Huang H, Qian G, Yu T.
    • Endocr Relat Cancer. 2018 Jan;25(1):69-82. doi: 10.1530/ERC-17-0261. Epub 2017 Oct 24.
    • BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
    • Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T.
    • Int J Gynecol Cancer. 2018 Jan;28(1):69-76. doi: 10.1097/IGC.0000000000001144.
    • Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
    • Jin M, Cai J, Wang X, Zhang T, Zhao Y.
    • Cancer Biol Ther. 2018;19(12):1088-1092. doi: 10.1080/15384047.2018.1491500. Epub 2018 Aug 15.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • PARP Inhibitors in Epithelial Ovarian Cancer.
    • Taylor KN, Eskander RN.
    • Recent Pat Anticancer Drug Discov. 2018;13(2):145-158. doi: 10.2174/1574892813666171204094822.
    • Olaparib.
    • Bochum S, Berger S, Martens UM.
    • Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
    • Review

Continue to Older References